## metadata
source file: data/floodlamp/reg/fda-townhalls/f5_fixnames/run_auto/2021-09-22_Virtual Town Hall 70_fixnames.md
last updated: 2025-01-04 Created QA Sections
link pdf: https://www.fda.gov/media/152888/download?attachment
link youtube: https://youtu.be/C2bwFnORLFI
link slides: 
topic: COVID-19


## content

### removed qa blocks
QA Block 4-5
CLARIFIED QUESTION: Can the same set of samples be used to support claims for both total and neutralizing antibodies in a multi-indication test?
CLARIFIED ANSWER: The same set of samples may not support claims for both total and neutralizing antibodies simultaneously, and additional samples may be needed to validate multiple indications.
VERBATIM QUESTION: Can the same set of samples be used to support claims for both total and neutralizing antibodies in a multi-indication test?
VERBATIM ANSWER: Since the validation and considerations for neutralizing antibody tests are different from binding antibody tests, the same samples may not be able to support all proposed claims simultaneously, and additional samples may be appropriate to validate multiple indications.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Validation requirements, Neutralizing vs. total antibodies, Sample use limitations
REVIEW FLAG: False

QA Block 8-3
CLARIFIED QUESTION: How long does it take for the FDA to respond to questions submitted through the CDRH EUA Templates email address?
CLARIFIED ANSWER: If FDA has not responded to an inquiry via the CDRH EUA Templates email address within a couple of weeks, users are advised to send a follow-up email.
VERBATIM QUESTION: How long does it take for the FDA to respond to questions submitted through the CDRH EUA Templates email address?
VERBATIM ANSWER: If it's been more than a couple of weeks, you can go ahead and send an another email to the Templates email address and ask them, in this case, to contact Toby.
SPEAKER QUESTION: Julio Herrera
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: response time, CDRH EUA Templates email, FDA correspondence
REVIEW FLAG: False

QA Block 9-1
CLARIFIED QUESTION: Is it quicker to submit a pre-EUA and then an EUA, or to submit the EUA directly for the application?
CLARIFIED ANSWER: FDA generally recommends submitting an EUA directly for routine assay tests as it saves time and is low-risk when following FDA templates.
VERBATIM QUESTION: Is it quicker to submit a pre-EUA and then an EUA, or to submit the EUA directly for the application?
VERBATIM ANSWER: Yeah, so for most EUA submissions today for routine sort of assay tests, we've got templates for all recommendations for all the studies. And there are lots of authorizations for all these common types of tests. So I really don't believe there's any need for pre-EUA and would not recommend that pre-EUAs be used in those circumstances, but that you go right ahead and do your EUA. And that will save a lot of time. There is some risks, as always. But if you're doing exactly what others have done in the same manner, and according to our template, the risks are very, very small.
SPEAKER QUESTION: Tianyang Liu
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA submission process, Pre-EUA vs EUA
REVIEW FLAG: False

QA Block 9-7
CLARIFIED QUESTION: Does the FDA prioritize reviewing EUAs over pre-EUAs when there is a backlog of submissions?
CLARIFIED ANSWER: The FDA prioritizes reviewing EUAs over pre-EUAs, particularly in cases where the EUA submissions follow standard recommendations and templates. Pre-EUAs are best used for novel or non-standard cases.
VERBATIM QUESTION: Does the FDA prioritize reviewing EUAs over pre-EUAs when there is a backlog of submissions?
VERBATIM ANSWER: So, we are still receiving so many applications and still have a backlog. And we're trying to get through everything. And again, it's why I don't recommend a pre-EUA if you're just fine with standard recommendations that the FDA makes for standard devices. People should reserve the pre-EUA for something novel, something new, something that we haven't discussed on this town hall, something that isn't in the templates, something there isn't a template for. That's where you get the most bang for the buck on the pre-EUA. We do make some recommendations about pre-EUA. But that's not global and it's very specific and is trying to manage the workflow that we have. So we have a lot of EUAs in house. And when we have an EUA in house, where perhaps all the studies were done and the tests can be authorized, it seems a little bit more important for us to review that than a pre-EUA for something that's very standard. But we're trying to get to all the work. It's just a lot of work.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA review prioritization, backlog management, pre-EUA vs EUA
REVIEW FLAG: False

QA Block 11-8
CLARIFIED QUESTION: Is there potential for the US government to fund similar large-scale validation projects for antigen tests?
CLARIFIED ANSWER: The FDA considers a government-funded validation program for antigen tests as an interesting and valuable idea, highlighting the success of a similar serology program. However, it would require significant funding and collaboration, and FDA will take the idea back for discussion.
VERBATIM QUESTION: Is there potential for the US government to fund similar large-scale validation projects for antigen tests?
VERBATIM ANSWER: Your idea of a US government stood-up program to evaluate antigen tests is an interesting one. Of course, the FDA and NCI and CDC stood up a program for the serology test developers. And I forget the latest number on serology tests, but we authorized almost 90, if not over 90 serology tests, many of them lateral flow devices very similar to antigen tests through that program. And it's an interesting idea, and very willing to take that back. That program at the NCI was funded. And it took a lot of money to do that program. I don't know if the budget numbers are public. But I know the amount and it was not insignificant. And obviously, I would be very supportive of something like that, because an independent assessment by the US government is quite valuable. And as we found out with the serology test, and I think I've mentioned this multiple times before on this call, those tests that were submitted to NCI and were cleared by the FDA to be tested at NCI, we did an initial review of all submissions only recommended to NCI those tests that after our initial review seemed important to test. So we did eliminate from the list before NCI tested, and still something like 60% to 70% of the tests that had passed that first FDA review failed at NCI. And so this kind of program can be very helpful for challenging questions. And I think it's a really good idea and definitely will take that back.
SPEAKER QUESTION: Franco Calderon
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: antigen test validation, government funding, program feasibility
REVIEW FLAG: False


### extract log
#### extract log header
datetime: 2025-01-04 08:46:35 UTC-08:00 America/Los_Angeles
source file prep: primary.llm.add_transcript_section_delimiters for non-FDA speakers
ROUND 1 NAME: Explicit Questions Extraction
- prompt: FCALL_SYSTEM_PROMPT_QA_QONLY_EXPLICIT_1D
- tools: tools_qa_qonly_explicit_1
- provider: openai
- model: gpt-4o-2024-11-20

#### Section 1 of 16
##### Explicit Questions Extraction

##### Implicit Questions Extraction
QI 1-1: What steps should high-complexity labs follow to implement the Abbot Alinity m update before EUA authorization?
QI 1-2: What is the expected timeline for the FDA to complete the review of the Abbot Alinity m update?
QI 1-3: What specific issues caused the false positive results in the Abbott Alinity m test?
QI 1-4: What does the FDA recommend for handling potential false positives from the prior two weeks of Abbott Alinity m tests?
QI 1-5: What are the FDA's criteria for extending EUA-authorized updates to all labs, including moderate complexity labs?
QI 1-6: How can test developers ensure faster feedback on their EUA submissions for antigen tests?

#### Section 2 of 16
##### Explicit Questions Extraction
QE 2-1: Do self-collection swabs for a home-use novel amplified signal lateral flow device need to be FDA EUA authorized, or can any FDA-cleared swab be used, provided they are validated and part of usability and clinical studies?
QE 2-2: Is it possible to get further clarification on what the FDA defines as consecutively-collected samples in relation to pooling guidance for molecular and antigen diagnostic tests?
QE 2-3: For consecutively-collected samples, does it mean the same person must return to the collection site for multiple visits to collect new swabs?
QE 2-4: For consecutively-collected samples, does it mean only the initial sample should be tested in a consecutive manner?

##### Implicit Questions Extraction
QI 2-1: Can mid-turbinate swabs be used for children if additional safety measures are in place?
QI 2-2: Why are nasopharyngeal (NP) and oropharyngeal (OP) swabs not recommended for home-use diagnostic tests?
QI 2-3: What constitutes a reasonable explanation for omitting eligible subject samples during the study?
QI 2-4: What is the importance of consulting the FDA when designing a serial testing validation study?
QI 2-5: Are there specific methods recommended by the FDA to ensure samples are collected from all eligible study subjects without omissions?

#### Section 3 of 16
##### Explicit Questions Extraction
QE 3-1: After a two-week prospective time period of collecting and testing when zero flu samples have been obtained, is it possible to supplement with all bank specimens for clinical study validation?
QE 3-2: For the same scenario, would the FDA require a post-market study with fresh samples when flu samples are more readily available?

##### Implicit Questions Extraction
QI 3-1: Can a clinical validation study using bank samples be conducted at more than one testing site?
QI 3-2: What are the specific challenges involved in validating combined SARS and flu antigen tests?
QI 3-3: What should be included in the study design for combined molecular SARS and flu tests when submitting it to the FDA?
QI 3-4: Does the FDA have specific recommendations for obtaining archived flu-positive specimens for validation studies?

#### Section 4 of 16
##### Explicit Questions Extraction
QE 4-1: Which EUA template does the FDA recommend using for a test that detects both total and neutralizing antibodies simultaneously?
QE 4-2: Does the FDA have any other recommendations for a test that evaluates both total and neutralizing antibodies simultaneously?

##### Implicit Questions Extraction
QI 4-1: What is the FDA's guidance for integrating portions of multiple EUA templates into a single EUA submission?
QI 4-2: Are additional samples always required when validating a test with multiple indications, such as total and neutralizing antibodies?
QI 4-3: Can the same set of samples be used to support claims for both total and neutralizing antibodies in a multi-indication test?
QI 4-4: What are the specific study design considerations unique to tests that detect both binding and neutralizing antibodies?
QI 4-5: Should developers submit pre-EUA questions to clarify aspects of combining validation requirements from different EUA templates?

#### Section 5 of 16
##### Explicit Questions Extraction
QE 5-1: Could you confirm that changes to an EUA-authorized test can be enacted at high complexity labs while the amendment is still under FDA review?
QE 5-2: Could you provide additional details with respect to the policy regarding amendments to EUA applications?

##### Implicit Questions Extraction
QI 5-1: What are the limitations for using tests in environments other than high complexity CLIA-certified laboratories before an EUA is issued?
QI 5-2: Does the modification policy apply differently to new tests and unauthorized modifications?
QI 5-3: What constitutes an unauthorized modification under the FDA's policy for EUA amendments?
QI 5-4: How should laboratories ensure compliance with CLIA requirements when implementing modifications still under FDA review?
QI 5-5: Are there specific criteria that an infield correction must meet under the current EUA policies?

#### Section 6 of 16
##### Explicit Questions Extraction
QE 6-1: If we want to implement changes to our devices and test kits, do we need to complete our current original study design, prospectively collecting 30 positives and 30 negatives, before starting a new trial with the updated device designs?
QE 6-2: Can we terminate our study prematurely and start a new study design with the new device design?
QE 6-3: Would it be possible to start this new study design at the same study site, or do we need to look for a new study site to conduct this repeat validation study?

##### Implicit Questions Extraction
QI 6-1: What is the recommended approach to testing multiple device designs in a clinical trial to avoid bias?
QI 6-2: Can we use the same clinical site staff and subjects for testing both the original and updated device designs?
QI 6-3: Are there specific procedures for using buffers common to multiple devices in order to ensure unbiased results?
QI 6-4: What precautions should be taken when testing multiple samples from the same patient to prevent bias?
QI 6-5: How should developers proceed in validating changes to a device while fulfilling original EUA commitments?

#### Section 7 of 16
##### Explicit Questions Extraction
QE 7-1: Can you clarify where and how healthcare providers would be involved with multi-analyte panel tests, such as whether they are just writing a prescription for the test or also being involved during result interpretation?
QE 7-2: Even for a multi-analyte panel that tests for both flu and SARS-CoV-2, can the same recommendations for flu-exempt tests be applied?
QE 7-3: If a robust usability study demonstrates high user comprehension for flu and SARS-CoV-2 test results, could that reopen discussions about OTC authorization instead of prescription-only use?
QE 7-4: When you say 'physician contact,' does it mean that the result has to go through a healthcare provider before release, or is it just encouraged that an HCP is available to assist upon receiving results?

##### Implicit Questions Extraction
QI 7-1: What guidance does the FDA provide on labeling and instructions for home-use prescription tests for COVID-19 and flu?
QI 7-2: Under what conditions should patients report their home test results to a clinician, and what role does clinical consultation play in interpreting these results?
QI 7-3: What additional mitigations does the FDA recommend for prescription authorization of home tests?
QI 7-4: Are there differences in guidance for labeling in home-use scenarios that involve prescription versus OTC tests?
QI 7-5: How does the FDA view the inclusion of other analytes like flu or RSV in differential diagnosis for asymptomatic versus symptomatic individuals in the context of EUA?
QI 7-6: What specific clinician and patient interaction or access requirements must be established in home test approval considerations?

#### Section 8 of 16
##### Explicit Questions Extraction
QE 8-1: For confirming positive results in the clinical agreement section for serology assays, can an FDA EUA antigen or rapid test, such as the BinaxNOW, be used as a positive confirmatory test?
QE 8-2: Are vaccinated individuals, who are four to six months past their last dose and are now sending a confirmatory positive result, eligible to be considered confirmed positives for the clinical agreement or usability?
QE 8-3: How long does it take for the FDA to respond to questions submitted through the CDRH EUA Templates email address?

##### Implicit Questions Extraction
QI 8-1: What should developers do if a test- or case-specific question cannot be addressed during the FDA Town Hall meeting?
QI 8-2: Who should developers contact if they have already been assigned a reviewer but still need additional clarification on their submission?
QI 8-3: Is there a specific protocol to follow if developers have not received a timely response from the CDRH EUA Templates email address?

#### Section 9 of 16
##### Explicit Questions Extraction
QE 9-1: Is it quicker to submit a pre-EUA and then an EUA, or to submit the EUA directly for the application?
QE 9-2: Which submission approach do you recommend: submitting a pre-EUA first or submitting the EUA directly?
QE 9-3: If a submission protocol is really good, could it take longer for the FDA team to respond initially but proceed quickly after receiving official feedback?

##### Implicit Questions Extraction
QI 9-1: What are the risks associated with bypassing the pre-EUA process if developers follow existing templates?
QI 9-2: Under what circumstances is submitting a pre-EUA beneficial?
QI 9-3: Are there FDA recommendations for using a pre-EUA specifically for novel or non-template-based submissions?
QI 9-4: Does the FDA prioritize reviewing EUAs over pre-EUAs when there is a backlog of submissions?
QI 9-5: How does the FDA determine what qualifies as something 'novel' for prioritizing pre-EUAs?
QI 9-6: What workflow management practices does the FDA use to handle the EUA and pre-EUA submission backlog?

#### Section 10 of 16
##### Explicit Questions Extraction
QE 10-1: Can we now submit an EUA using just saliva specimens for approval for COVID diagnosis?
QE 10-2: Would a nasal turbinate swab be an acceptable comparison?

##### Implicit Questions Extraction
QI 10-1: What is the FDA's current stance on the performance of saliva-based diagnostics for detecting viruses beyond COVID-19, such as flu or RSV?
QI 10-2: Does the FDA require any additional data for saliva-based diagnostics to ensure accuracy across different respiratory viruses?
QI 10-3: How should developers interpret data indicating lower viral load in saliva specimens compared to nasal or nasopharyngeal swabs when validating tests?
QI 10-4: Has the FDA observed substantial performance variability in saliva-based diagnostic tests submitted for EUA?

#### Section 11 of 16
##### Explicit Questions Extraction
QE 11-1: Do you see FDA, CDC, NIH, or any organization taking a more active role in helping test developers with the validation of tests, similar to programs in countries like the UK or Germany?
QE 11-2: Could the US government implement a program to evaluate and validate antigen tests similar to the established program for serology tests?

##### Implicit Questions Extraction
QI 11-1: What is the FDA's current prioritization process for reviewing COVID-19 antigen test applications?
QI 11-2: How does the FDA plan to address the economic challenges test developers face in getting their tests validated by US institutions?
QI 11-3: Could a government-led funding program make the antigen test evaluation process more accessible to test developers?
QI 11-4: How does the FDA's initial review process determine which tests are forwarded to NCI for evaluation?
QI 11-5: What specific lessons from the serology evaluation program could be applied to antigen test evaluations?
QI 11-6: Is there potential for the US government to fund similar large-scale validation projects for antigen tests?
QI 11-7: What are the limitations or bottlenecks preventing non-US companies from accessing funds aimed at increasing rapid test availability in the US?
QI 11-8: Would the FDA support or recommend alternative government strategies for purchasing and distributing diagnostic tests outside of commercial channels?

#### Section 12 of 16
##### Explicit Questions Extraction
QE 12-1: Once satisfied that performance is equivalent to the current authorized test, can we implement changes to an EUA test in high complexity CLIA labs while the EUA is under FDA review?
QE 12-2: When submitting the EUA along with a cover letter, should it indicate that we are going to immediately implement software changes?
QE 12-3: Could you clarify the provisions or timeline for implementing modifications to a commercial diagnostic COVID test in high complexity labs?

##### Implicit Questions Extraction
QI 12-1: What is the exact time frame required for validating modifications to an EUA-authorized test before implementation in high complexity labs?
QI 12-2: Is the timeline for validation of modifications similar to the validation of a new diagnostic device?
QI 12-3: Should policy guidance for validating modifications also address the steps required for submitting amendments for authorization?
QI 12-4: Are there any specific provisions for overseeing the implementation of software-related modifications in high complexity labs?

#### Section 13 of 16
##### Explicit Questions Extraction
QE 13-1: What do you recommend as a way or path forward for submission in the absence of feedback from FDA for validating multiplex devices, especially with a lack of prospective samples for influenza?
QE 13-2: When I resubmit, should I request that the information gets forwarded to Toby?
QE 13-3: When can I expect the more recent transcripts of the FDA town halls to be posted?
QE 13-4: Should I submit everything as-is and explain to FDA?
QE 13-5: Should I provide my pre-EUA number when resubmitting my question?

##### Implicit Questions Extraction
QI 13-1: Why is VTM (viral transport media) discouraged for use with antigen tests?
QI 13-2: What are the acceptable alternatives to banked direct swabs for antigen test validation?
QI 13-3: How can antigen test manufacturers address challenges with visual read devices that include multiple analytes, such as flu and SARS?
QI 13-4: What should developers do if there are no flu cases to validate influenza targets for multiplex devices?
QI 13-5: Can additional targets on a multiplex device be turned off to allow for partial authorization for only SARS-CoV-2?
QI 13-6: What steps are needed to re-enable other analytes on a multiplex test once sufficient data is available for validation and authorization?
QI 13-7: Are there specific considerations for modifying test designs to prevent user confusion when testing for multiple analytes?

#### Section 14 of 16
##### Explicit Questions Extraction
QE 14-1: Are the notification pathways for antibody tests still viable pathways for manufacturers to use in order to market to high complexity settings while waiting for their EUA?

##### Implicit Questions Extraction
QI 14-1: What should manufacturers do if their device notifications do not appear timely on the FDA notification page?
QI 14-2: Are there any cases where commercial manufacturers are exempt from the requirement to post notification for their devices?

#### Section 15 of 16
##### Explicit Questions Extraction
QE 15-1: In a clinical trial for a multi-analyte antigen detection test, if a reference RT-PCR assay does not have claims for a specific specimen type, but the reference laboratory we're using has validated that specimen type, is it acceptable to use the results from that lab-validated specimen as a reference?

##### Implicit Questions Extraction
QI 15-1: What are the FDA's recommendations for using EUA-authorized methods as comparators in test validations?
QI 15-2: Can a molecular test with laboratory-developed test (LDT) modifications be used without additional FDA review?
QI 15-3: What does the FDA mean by 'authorizable' when describing test modifications?
QI 15-4: How does reliance on testing methods with unauthorized modifications affect the efficiency of the FDA review process?
QI 15-5: Why does the FDA prefer fully cleared or EUA-authorized molecular tests as comparators over modified tests?

#### Section 16 of 16
##### Explicit Questions Extraction
QE 16-1: Which comparator method would be recommended for a test developer pursuing a 510k with a SARS-CoV-2 assay using anterior nares samples?
QE 16-2: Should a nasal swab be validated on the BioFire assay before using it as a comparator method?
QE 16-3: Should an EUA-authorized assay that uses a nasal swab be used as a comparator instead, and why?

##### Implicit Questions Extraction

### qa


#### 1. Updates on SARS-CoV-2 Testing and EUA Reviews

QA Block 1-1
CLARIFIED QUESTION: What steps should high-complexity labs follow to implement the Abbot Alinity m update before EUA authorization?
CLARIFIED ANSWER: High-complexity labs can implement the Abbot Alinity m update if they choose, while the FDA reviews it and prior to EUA authorization.
VERBATIM QUESTION: What steps should high-complexity labs follow to implement the Abbot Alinity m update before EUA authorization?
VERBATIM ANSWER: In the meantime, the firm can launch that update into high complexity labs only, if those labs wish to have that update, while the FDA reviews the update and prior to EUA authorization.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Abbot Alinity m update, High-complexity labs, EUA process
REVIEW FLAG: False

QA Block 1-2
CLARIFIED QUESTION: What is the expected timeline for the FDA to complete the review of the Abbot Alinity m update?
CLARIFIED ANSWER: The FDA is reviewing the Abbot Alinity m update to determine its effectiveness. While under review, the update may be used in high-complexity labs, but broader authorization will occur after completion.
VERBATIM QUESTION: What is the expected timeline for the FDA to complete the review of the Abbot Alinity m update?
VERBATIM ANSWER: The company thinks they understand the cause. The company thinks they have a fix. The FDA is currently reviewing that fix to see if it indeed works. In the meantime, the firm can launch that update into high complexity labs only, if those labs wish to have that update, while the FDA reviews the update and prior to EUA authorization. When the FDA updates the EUA authorization with a fix or a mitigation that can be extended to all labs, including moderate and complex labs, then we will do so, and the firm can go ahead and update the software in all those labs too.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Abbot Alinity m review, FDA EUA process, COVID-19 diagnostics
REVIEW FLAG: False

QA Block 1-3
CLARIFIED QUESTION: What specific issues caused the false positive results in the Abbott Alinity m test?
CLARIFIED ANSWER: The false positive results in the Abbott Alinity m test were due to a design issue.
VERBATIM QUESTION: What specific issues caused the false positive results in the Abbott Alinity m test?
VERBATIM ANSWER: So there was a design issue with the Abbot Alinity m that resulted in confirmed false positive. Don't know the exact rate.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Abbott Alinity m test, false positives, test design issue
REVIEW FLAG: False

QA Block 1-4
CLARIFIED QUESTION: What does the FDA recommend for handling potential false positives from the prior two weeks of Abbott Alinity m tests?
CLARIFIED ANSWER: The FDA recommends retesting positives from the prior two weeks of Abbott Alinity m test cases using another SARS-CoV-2 molecular test to confirm the positives.
VERBATIM QUESTION: What does the FDA recommend for handling potential false positives from the prior two weeks of Abbott Alinity m tests?
VERBATIM ANSWER: So we do recommend that the prior two weeks of cases, that you look and see if you were to retest those positives to confirm the positive with another SARS-CoV-2 molecular test.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Abbott Alinity m false positives, Retesting recommendation, SARS-CoV-2 molecular testing
REVIEW FLAG: False

QA Block 1-5
CLARIFIED QUESTION: What are the FDA's criteria for extending EUA-authorized updates to all labs, including moderate complexity labs?
CLARIFIED ANSWER: The FDA extends EUA-authorized updates to all labs, including moderate complexity labs, after confirming a fix or mitigation through the EUA authorization process.
VERBATIM QUESTION: What are the FDA's criteria for extending EUA-authorized updates to all labs, including moderate complexity labs?
VERBATIM ANSWER: When the FDA updates the EUA authorization with a fix or a mitigation that can be extended to all labs, including moderate and complex labs, then we will do so, and the firm can go ahead and update the software in all those labs too.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA criteria, Lab updates, Authorization process
REVIEW FLAG: False

QA Block 1-6
CLARIFIED QUESTION: How can test developers ensure faster feedback on their EUA submissions for antigen tests?
CLARIFIED ANSWER: FDA is prioritizing EUA submissions, especially for point-of-care and home tests, by adding personnel to the antigen review team and focusing on reducing turnaround times.
VERBATIM QUESTION: How can test developers ensure faster feedback on their EUA submissions for antigen tests?
VERBATIM ANSWER: As we stated, it's a high priority for us to review these submissions, particularly point-of-care and home tests. We have added more personnel from other EUA review areas onto the antigen team. And we are making a concerted effort to reduce the turnaround time for those submissions. Some developers have started getting feedback. And we plan to get through all the current submissions as rapidly as possible. And we hope this becomes evident over the days and weeks ahead.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA submissions, faster feedback, antigen tests
REVIEW FLAG: False


#### 2. FDA Guidance on Swabs and Serial Testing Validation

QA Block 2-1
CLARIFIED QUESTION: Do self-collection swabs for a home-use novel amplified signal lateral flow device need to be FDA EUA authorized, or can any FDA-cleared swab be used, provided they are validated and part of usability and clinical studies?
CLARIFIED ANSWER: FDA recommends nasal swabs for home use. Mid-turbinate swabs may also be used if safe, especially for children. NP and OP swabs are not recommended. FDA allows FDA-cleared swabs (510k) to be used, provided they are validated and included in usability and clinical studies.
VERBATIM QUESTION: Do self-collection swabs for a home-use novel amplified signal lateral flow device need to be FDA EUA authorized, or can any FDA-cleared swab be used, provided they are validated and part of usability and clinical studies?
VERBATIM ANSWER: So the FDA does recommend nasal swabs for home use. Mid-turbinate swabs may be used if safe, especially for children. Typically, for children, in particular there'll be some method to prevent the swab from going up too far. NP and OP swabs are not recommended. Now, one second. So, bottom line is that swabs can be used that are FDA 510k cleared, as long as they're validated and part of the clinical and usability studies.
SPEAKER QUESTION: Tim Stenzel (FDA IVD Director)
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Self-collection swabs, Home diagnostic devices, FDA EUA and 510k clearance
REVIEW FLAG: False

QA Block 2-2
CLARIFIED QUESTION: Is it possible to get further clarification on what the FDA defines as consecutively-collected samples in relation to pooling guidance for molecular and antigen diagnostic tests?
CLARIFIED ANSWER: Consecutively collected samples refer to all samples from eligible and unique study subjects collected during the study period. No eligible samples should be omitted without a reasonable explanation. FDA advises consulting on the design of complex serial testing studies to minimize burden.
VERBATIM QUESTION: Is it possible to get further clarification on what the FDA defines as consecutively-collected samples in relation to pooling guidance for molecular and antigen diagnostic tests?
VERBATIM ANSWER: So, consecutively collected samples are all the samples that are collected from eligible and unique study subjects between the start and end date of the study. During the study, no samples from eligible subjects should be omitted from the analysis. So, in other words, pick a time period from if you're using any method of having those samples. We don't want to have subjects drop out, unless there's an explanation and a reasonable explanation for it. If you were designing a serial testing validation study, we recommend reaching out through a pre-EUA, or to your lead reviewer, to discuss details. This kind of serial testing validation study is rather complex and should only be implemented with input from the FDA to avoid unnecessary burden.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Pooling guidance, Consecutively-collected samples, Study design
REVIEW FLAG: False

QA Block 2-3
CLARIFIED QUESTION: For consecutively-collected samples, does it mean the same person must return to the collection site for multiple visits to collect new swabs?
CLARIFIED ANSWER: Consecutively collected samples refer to all samples collected from unique, eligible study subjects during the study period. Subjects are not required to return for multiple visits unless specified, as all samples must be included in the analysis unless an omission is justified.
VERBATIM QUESTION: For consecutively-collected samples, does it mean the same person must return to the collection site for multiple visits to collect new swabs?
VERBATIM ANSWER: So, consecutively collected samples are all the samples that are collected from eligible and unique study subjects between the start and end date of the study. During the study, no samples from eligible subjects should be omitted from the analysis. So, in other words, pick a time period from if you're using any method of having those samples. We don't want to have subjects drop out, unless there's an explanation and a reasonable explanation for it.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: consecutively-collected samples, study design, sample analysis
REVIEW FLAG: False

QA Block 2-4
CLARIFIED QUESTION: For consecutively-collected samples, does it mean only the initial sample should be tested in a consecutive manner?
CLARIFIED ANSWER: Consecutively collected samples include all samples collected from eligible and unique study subjects during the study period, and none should be excluded without a valid reason. Testing should follow a defined time period and involve consultation with the FDA for complex designs.
VERBATIM QUESTION: For consecutively-collected samples, does it mean only the initial sample should be tested in a consecutive manner?
VERBATIM ANSWER: So, consecutively collected samples are all the samples that are collected from eligible and unique study subjects between the start and end date of the study. During the study, no samples from eligible subjects should be omitted from the analysis. So, in other words, pick a time period from if you're using any method of having those samples. We don't want to have subjects drop out, unless there's an explanation and a reasonable explanation for it. If you were designing a serial testing validation study, we recommend reaching out through a pre-EUA, or to your lead reviewer, to discuss details. This kind of serial testing validation study is rather complex and should only be implemented with input from the FDA to avoid unnecessary burden.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Consecutively collected samples, Serial testing validation, Study design
REVIEW FLAG: False

QA Block 2-5
CLARIFIED QUESTION: Can mid-turbinate swabs be used for children if additional safety measures are in place?
CLARIFIED ANSWER: Mid-turbinate swabs can be used for children if additional safety measures, such as preventing the swab from going too far, are in place.
VERBATIM QUESTION: Can mid-turbinate swabs be used for children if additional safety measures are in place?
VERBATIM ANSWER: Mid-turbinate swabs may be used if safe, especially for children. Typically, for children, in particular there'll be some method to prevent the swab from going up too far.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Mid-turbinate swabs usage, Safety measures for children
REVIEW FLAG: False

QA Block 2-6
CLARIFIED QUESTION: Why are nasopharyngeal (NP) and oropharyngeal (OP) swabs not recommended for home-use diagnostic tests?
CLARIFIED ANSWER: The FDA recommends nasal swabs for home use because they are safer and easier for self-collection. NP and OP swabs are not recommended for home use.
VERBATIM QUESTION: Why are nasopharyngeal (NP) and oropharyngeal (OP) swabs not recommended for home-use diagnostic tests?
VERBATIM ANSWER: So the FDA does recommend nasal swabs for home use. Mid-turbinate swabs may be used if safe, especially for children. Typically, for children, in particular there'll be some method to prevent the swab from going up too far. NP and OP swabs are not recommended.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Swab types for home tests, Safety of swabs, FDA recommendations
REVIEW FLAG: False

QA Block 2-7
CLARIFIED QUESTION: What constitutes a reasonable explanation for omitting eligible subject samples during the study?
CLARIFIED ANSWER: Samples from eligible subjects must not be excluded unless there is a reasonable explanation for their omission during the analysis.
VERBATIM QUESTION: IMPLICIT
VERBATIM ANSWER: No samples from eligible subjects should be omitted from the analysis. So, in other words, pick a time period from if you're using any method of having those samples. We don't want to have subjects drop out, unless there's an explanation and a reasonable explanation for it.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: study sample omission, eligible subjects, FDA recommendations
REVIEW FLAG: False

QA Block 2-8
CLARIFIED QUESTION: What is the importance of consulting the FDA when designing a serial testing validation study?
CLARIFIED ANSWER: The FDA recommends consulting through a pre-EUA or lead reviewer when designing a serial testing validation study due to its complexity, to avoid unnecessary burden.
VERBATIM QUESTION: What is the importance of consulting the FDA when designing a serial testing validation study?
VERBATIM ANSWER: If you were designing a serial testing validation study, we recommend reaching out through a pre-EUA, or to your lead reviewer, to discuss details. This kind of serial testing validation study is rather complex and should only be implemented with input from the FDA to avoid unnecessary burden.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Serial testing validation, FDA consultation, Study design
REVIEW FLAG: False

QA Block 2-9
CLARIFIED QUESTION: Are there specific methods recommended by the FDA to ensure samples are collected from all eligible study subjects without omissions?
CLARIFIED ANSWER: Consecutively collected samples must include all eligible and unique study subjects' samples from the start to the end of the study without omissions. If subjects drop out, a reasonable explanation is required, and consultation with the FDA is recommended for serial testing validation studies.
VERBATIM QUESTION: IMPLICIT
VERBATIM ANSWER: Consecutively collected samples are all the samples that are collected from eligible and unique study subjects between the start and end date of the study. During the study, no samples from eligible subjects should be omitted from the analysis. So, in other words, pick a time period from if you're using any method of having those samples. We don't want to have subjects drop out, unless there's an explanation and a reasonable explanation for it. If you were designing a serial testing validation study, we recommend reaching out through a pre-EUA, or to your lead reviewer, to discuss details.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: sample collection methods, serial testing studies, FDA recommendations
REVIEW FLAG: False


#### 3. Prospective and Bank Samples for Flu Device Validation

QA Block 3-1
CLARIFIED QUESTION: After a two-week prospective time period of collecting and testing when zero flu samples have been obtained, is it possible to supplement with all bank specimens for clinical study validation?
CLARIFIED ANSWER: After a two-week prospective study, using bank samples for clinical validation is permissible at one testing site. However, testing archived positive and negative samples is recommended to support authorization, even if challenging. A complete post-authorization study with fresh samples will likely be required.
VERBATIM QUESTION: After a two-week prospective time period of collecting and testing when zero flu samples have been obtained, is it possible to supplement with all bank specimens for clinical study validation?
VERBATIM ANSWER: After the two week duration, clinical validation study using bank samples may be conducted at one testing site. You should test archived samples, both positive and negative. We acknowledge the reduced prevalence of influenza last season and so far this year, and that archived specimens may be difficult to obtain. However, we still recommend testing archived samples to support authorization. There will likely be a commitment for a complete post-authorization study, as discussed using fresh samples. The antigen test validation in this situation for combined SARS and flu devices has particular challenges with it. And the FDA does recommend that you discuss your study design for that with the FDA first.
SPEAKER QUESTION: Tim Stenzel (FDA IVD Director)
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: use of bank specimens, clinical validation study, post-authorization requirements
REVIEW FLAG: False

QA Block 3-2
CLARIFIED QUESTION: For the same scenario, would the FDA require a post-market study with fresh samples when flu samples are more readily available?
CLARIFIED ANSWER: The FDA allows clinical validation studies using bank samples after two weeks of prospective testing and recommends testing archived samples even with reduced flu prevalence. A post-market study with fresh samples will likely be required.
VERBATIM QUESTION: For the same scenario, would the FDA require a post-market study with fresh samples when flu samples are more readily available?
VERBATIM ANSWER: After the two week duration, clinical validation study using bank samples may be conducted at one testing site. You should test archived samples, both positive and negative. We acknowledge the reduced prevalence of influenza last season and so far this year, and that archived specimens may be difficult to obtain. However, we still recommend testing archived samples to support authorization. There will likely be a commitment for a complete post-authorization study, as discussed using fresh samples.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: post-market study, fresh and bank samples, SARS and flu diagnostics
REVIEW FLAG: False

QA Block 3-3
CLARIFIED QUESTION: Can a clinical validation study using bank samples be conducted at more than one testing site?
CLARIFIED ANSWER: A clinical validation study using bank samples can only be conducted at one testing site after the two-week prospective study period, and both positive and negative archived samples should be tested.
VERBATIM QUESTION: Can a clinical validation study using bank samples be conducted at more than one testing site?
VERBATIM ANSWER: After the two week duration, clinical validation study using bank samples may be conducted at one testing site. You should test archived samples, both positive and negative.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: clinical validation, bank samples, testing site
REVIEW FLAG: False

QA Block 3-4
CLARIFIED QUESTION: What are the specific challenges involved in validating combined SARS and flu antigen tests?
CLARIFIED ANSWER: Validating combined SARS and flu antigen tests is particularly challenging, especially when using bank samples. FDA recommends discussing study designs in advance.
VERBATIM QUESTION: What are the specific challenges involved in validating combined SARS and flu antigen tests?
VERBATIM ANSWER: The antigen test validation in this situation for combined SARS and flu devices has particular challenges with it. And the FDA does recommend that you discuss your study design for that with the FDA first. There are challenges in using bank samples.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Antigen test validation, SARS and flu combined testing, Bank samples challenges
REVIEW FLAG: False

QA Block 3-5
CLARIFIED QUESTION: What should be included in the study design for combined molecular SARS and flu tests when submitting it to the FDA?
CLARIFIED ANSWER: The FDA recommends conducting a prospective clinical study for at least two weeks to evaluate combined molecular SARS and flu devices. If archived specimens are needed, testing both positive and negative samples can be done at one testing site, but developers should still plan for a post-authorization study using fresh samples when flu is more prevalent. The FDA advises discussing the study design in advance due to challenges associated with archived samples.
VERBATIM QUESTION: What should be included in the study design for combined molecular SARS and flu tests when submitting it to the FDA?
VERBATIM ANSWER: To evaluate the clinical performance of your combined device, a prospective clinical study should be conducted for at least two weeks, as the questioner stated. After the two week duration, clinical validation study using bank samples may be conducted at one testing site. You should test archived samples, both positive and negative. We acknowledge the reduced prevalence of influenza last season and so far this year, and that archived specimens may be difficult to obtain. However, we still recommend testing archived samples to support authorization. There will likely be a commitment for a complete post-authorization study, as discussed using fresh samples. The antigen test validation in this situation for combined SARS and flu devices has particular challenges with it. And the FDA does recommend that you discuss your study design for that with the FDA first. There are challenges in using bank samples.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: study design requirements, molecular SARS and flu tests, archived samples
REVIEW FLAG: False

QA Block 3-6
CLARIFIED QUESTION: Does the FDA have specific recommendations for obtaining archived flu-positive specimens for validation studies?
CLARIFIED ANSWER: The FDA recognizes the challenges in obtaining archived flu specimens but still recommends testing them for authorization. A post-authorization study using fresh samples will likely be required.
VERBATIM QUESTION: Does the FDA have specific recommendations for obtaining archived flu-positive specimens for validation studies?
VERBATIM ANSWER: We acknowledge the reduced prevalence of influenza last season and so far this year, and that archived specimens may be difficult to obtain. However, we still recommend testing archived samples to support authorization. There will likely be a commitment for a complete post-authorization study, as discussed using fresh samples.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Archived specimen testing, Flu test validation, Post-authorization study
REVIEW FLAG: False


#### 4. EUA Validation Guidance for Dual Antibody Tests

QA Block 4-1
CLARIFIED QUESTION: Which EUA template does the FDA recommend using for a test that detects both total and neutralizing antibodies simultaneously?
CLARIFIED ANSWER: FDA recommends using the total antibody template for total antibodies and the neutralizing antibody template for neutralizing antibodies. If neither template fully captures your test, combine applicable sections from both in a single EUA request, as different validations apply. Additional samples may be required for multiple claims, and detailed questions can be submitted through a pre-EUA.
VERBATIM QUESTION: Which EUA template does the FDA recommend using for a test that detects both total and neutralizing antibodies simultaneously?
VERBATIM ANSWER: So I mean, this is a good question. And the requirements of validation for both the recommendations that we make are different for both. So the FDA does recommend that developers complete all portions of a template that are relevant to their test. So for the total antibody, follow the templates for recommendations for total antibody. For neutralizing, follow the neutralizing antibody template. If there are validation recommends that are not covered in a single template but apply to your test, we recommend you provide the applicable sections from each template in a single EUA request. Since the validation and considerations for neutralizing antibody tests are different from binding antibody tests, the same samples may not be able to support all proposed claims simultaneously, and additional samples may be appropriate to validate multiple indications. For more discussion on study design aspects unique to this device, we recommend sending additional questions in through a pre-EUA.
SPEAKER QUESTION: Tim Stenzel (FDA IVD Director)
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA templates for antibody tests, Validation requirements, Pre-EUA guidance
REVIEW FLAG: False

QA Block 4-2
CLARIFIED QUESTION: Does the FDA have any other recommendations for a test that evaluates both total and neutralizing antibodies simultaneously?
CLARIFIED ANSWER: The FDA recommends completing all portions of relevant EUA templates for the test, including total and neutralizing antibody templates. If validation elements are missing from one template but are relevant, developers should incorporate applicable sections in a single EUA request. Additional samples may be required for multiple indications, and further inquiries can be submitted via a pre-EUA.
VERBATIM QUESTION: Does the FDA have any other recommendations for a test that evaluates both total and neutralizing antibodies simultaneously?
VERBATIM ANSWER: So I mean, this is a good question. And the requirements of validation for both the recommendations that we make are different for both. So the FDA does recommend that developers complete all portions of a template that are relevant to their test. So for the total antibody, follow the templates for recommendations for total antibody. For neutralizing, follow the neutralizing antibody template. If there are validation recommends that are not covered in a single template but apply to your test, we recommend you provide the applicable sections from each template in a single EUA request. Since the validation and considerations for neutralizing antibody tests are different from binding antibody tests, the same samples may not be able to support all proposed claims simultaneously, and additional samples may be appropriate to validate multiple indications. For more discussion on study design aspects unique to this device, we recommend sending additional questions in through a pre-EUA.
SPEAKER QUESTION: Tim Stenzel (FDA IVD Director)
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA recommendations, Neutralizing and total antibodies, Validation requirements
REVIEW FLAG: False

QA Block 4-3
CLARIFIED QUESTION: What is the FDA's guidance for integrating portions of multiple EUA templates into a single EUA submission?
CLARIFIED ANSWER: FDA recommends including all relevant sections from each applicable EUA template in a single submission. Developers should follow each template's specific recommendations and consider providing additional samples if necessary to validate multiple indications.
VERBATIM QUESTION: What is the FDA's guidance for integrating portions of multiple EUA templates into a single EUA submission?
VERBATIM ANSWER: The FDA does recommend that developers complete all portions of a template that are relevant to their test. So for the total antibody, follow the templates for recommendations for total antibody. For neutralizing, follow the neutralizing antibody template. If there are validation recommends that are not covered in a single template but apply to your test, we recommend you provide the applicable sections from each template in a single EUA request. Since the validation and considerations for neutralizing antibody tests are different from binding antibody tests, the same samples may not be able to support all proposed claims simultaneously, and additional samples may be appropriate to validate multiple indications.
SPEAKER QUESTION: Tim Stenzel (FDA IVD Director)
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA template integration, Validation requirements, Submission guidance
REVIEW FLAG: False

QA Block 4-4
CLARIFIED QUESTION: Are additional samples always required when validating a test with multiple indications, such as total and neutralizing antibodies?
CLARIFIED ANSWER: FDA states that additional samples may be necessary to validate multiple indications when the same samples cannot support all proposed claims.
VERBATIM QUESTION: Are additional samples always required when validating a test with multiple indications, such as total and neutralizing antibodies?
VERBATIM ANSWER: Since the validation and considerations for neutralizing antibody tests are different from binding antibody tests, the same samples may not be able to support all proposed claims simultaneously, and additional samples may be appropriate to validate multiple indications.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: test validation, neutralizing and binding antibodies, EUA requirements
REVIEW FLAG: False

QA Block 4-6
CLARIFIED QUESTION: What are the specific study design considerations unique to tests that detect both binding and neutralizing antibodies?
CLARIFIED ANSWER: FDA recommends developers follow the respective templates for total and neutralizing antibody tests and include all applicable sections in a single EUA request. Since validation for neutralizing antibody tests differs from binding antibody tests, the same samples might not support all claims, and additional samples may be needed. Further questions can be sent through a pre-EUA submission.
VERBATIM QUESTION: What are the specific study design considerations unique to tests that detect both binding and neutralizing antibodies?
VERBATIM ANSWER: The requirements of validation for both the recommendations that we make are different for both. So the FDA does recommend that developers complete all portions of a template that are relevant to their test. So for the total antibody, follow the templates for recommendations for total antibody. For neutralizing, follow the neutralizing antibody template. If there are validation recommends that are not covered in a single template but apply to your test, we recommend you provide the applicable sections from each template in a single EUA request. Since the validation and considerations for neutralizing antibody tests are different from binding antibody tests, the same samples may not be able to support all proposed claims simultaneously, and additional samples may be appropriate to validate multiple indications. For more discussion on study design aspects unique to this device, we recommend sending additional questions in through a pre-EUA.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: study design considerations, antibody test validation, EUA templates
REVIEW FLAG: False

QA Block 4-7
CLARIFIED QUESTION: Should developers submit pre-EUA questions to clarify aspects of combining validation requirements from different EUA templates?
CLARIFIED ANSWER: FDA recommends sending additional questions about study design aspects through a pre-EUA process if validation requirements from different EUA templates need clarification.
VERBATIM QUESTION: Should developers submit pre-EUA questions to clarify aspects of combining validation requirements from different EUA templates?
VERBATIM ANSWER: For more discussion on study design aspects unique to this device, we recommend sending additional questions in through a pre-EUA.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: pre-EUA process, validation requirements, EUA templates
REVIEW FLAG: False


#### 5. EUA Amendments and High Complexity CLIA Lab Policies

QA Block 5-1
CLARIFIED QUESTION: Could you confirm that changes to an EUA-authorized test can be enacted at high complexity labs while the amendment is still under FDA review?
CLARIFIED ANSWER: Yes, modifications to an EUA-authorized test under FDA review can be implemented in high complexity CLIA-certified laboratories, but use is restricted until an EUA is issued for expanded testing environments.
VERBATIM QUESTION: Could you confirm that changes to an EUA-authorized test can be enacted at high complexity labs while the amendment is still under FDA review?
VERBATIM ANSWER: So this question does reflect our policy. And I did mention this policy relative to the infield correction that Abbott Molecular is making for their Alinity m system for the SARS-only test and their SARS panel test. So as discussed in the previous town hall meeting, the COVID test policy guidance, as well as the FAQs on our website state, that unless and until an EUA is issued that authorize additional testing environments for a specific test under CLIA, use of that test is limited to laboratories certified to perform high complexity testing, including testing at the point of care when the site is covered by the laboratory's CLIA certificate for high complexity testing. This applies both to new tests and unauthorized modifications. So, yes, while the modification policy for commercial manufacturers of diagnostic tests provides for developers to implement modifications where they're still under FDA review, the implementation is limited to high complexity CLIA-certified laboratories.
SPEAKER QUESTION: Tim Stenzel (FDA IVD Director)
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA test modifications, CLIA high complexity testing, FDA review process
REVIEW FLAG: False

QA Block 5-2
CLARIFIED QUESTION: Could you provide additional details with respect to the policy regarding amendments to EUA applications?
CLARIFIED ANSWER: The FDA confirms that changes to EUA-authorized tests can be enacted at high complexity labs while under review. This applies to new tests and unauthorized modifications, per the COVID test policy guidance, and is detailed in FAQs on the FDA's website.
VERBATIM QUESTION: Could you provide additional details with respect to the policy regarding amendments to EUA applications?
VERBATIM ANSWER: So this question does reflect our policy. And I did mention this policy relative to the infield correction that Abbott Molecular is making for their Alinity m system for the SARS-only test and their SARS panel test. So as discussed in the previous town hall meeting, the COVID test policy guidance, as well as the FAQs on our website state, that unless and until an EUA is issued that authorize additional testing environments for a specific test under CLIA, use of that test is limited to laboratories certified to perform high complexity testing, including testing at the point of care when the site is covered by the laboratory's CLIA certificate for high complexity testing. This applies both to new tests and unauthorized modifications. So, yes, while the modification policy for commercial manufacturers of diagnostic tests provides for developers to implement modifications where they're still under FDA review, the implementation is limited to high complexity CLIA-certified laboratories.
SPEAKER QUESTION: Tim Stenzel (FDA IVD Director)
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA amendments, high complexity labs, COVID diagnostics policy
REVIEW FLAG: False

QA Block 5-3
CLARIFIED QUESTION: What are the limitations for using tests in environments other than high complexity CLIA-certified laboratories before an EUA is issued?
CLARIFIED ANSWER: Until an EUA is issued for additional environments, tests can only be used in high complexity CLIA-certified labs, including point of care if covered by such certification. This limitation applies to new tests and unauthorized modifications.
VERBATIM QUESTION: What are the limitations for using tests in environments other than high complexity CLIA-certified laboratories before an EUA is issued?
VERBATIM ANSWER: So as discussed in the previous town hall meeting, the COVID test policy guidance, as well as the FAQs on our website state, that unless and until an EUA is issued that authorize additional testing environments for a specific test under CLIA, use of that test is limited to laboratories certified to perform high complexity testing, including testing at the point of care when the site is covered by the laboratory's CLIA certificate for high complexity testing. This applies both to new tests and unauthorized modifications.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA limitations, CLIA-certified labs, Test environments
REVIEW FLAG: False

QA Block 5-4
CLARIFIED QUESTION: Does the modification policy apply differently to new tests and unauthorized modifications?
CLARIFIED ANSWER: The FDA's modification policy applies equally to new tests and unauthorized modifications, and these amendments can only be implemented at high complexity CLIA-certified laboratories during FDA review.
VERBATIM QUESTION: Does the modification policy apply differently to new tests and unauthorized modifications?
VERBATIM ANSWER: This applies both to new tests and unauthorized modifications. So, yes, while the modification policy for commercial manufacturers of diagnostic tests provides for developers to implement modifications where they're still under FDA review, the implementation is limited to high complexity CLIA-certified laboratories.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Modification policy, New tests, Unauthorized modifications
REVIEW FLAG: False

QA Block 5-5
CLARIFIED QUESTION: What constitutes an unauthorized modification under the FDA's policy for EUA amendments?
CLARIFIED ANSWER: Unauthorized modifications to EUA-authorized tests are subject to the FDA policy which allows implementation during review if conducted in high complexity CLIA-certified laboratories.
VERBATIM QUESTION: What constitutes an unauthorized modification under the FDA's policy for EUA amendments?
VERBATIM ANSWER: This applies both to new tests and unauthorized modifications. So, yes, while the modification policy for commercial manufacturers of diagnostic tests provides for developers to implement modifications where they're still under FDA review, the implementation is limited to high complexity CLIA-certified laboratories.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA amendments, unauthorized modifications, high complexity labs
REVIEW FLAG: False

QA Block 5-6
CLARIFIED QUESTION: How should laboratories ensure compliance with CLIA requirements when implementing modifications still under FDA review?
CLARIFIED ANSWER: Laboratories implementing unauthorized test modifications under FDA review must ensure compliance with CLIA by limiting use to high complexity CLIA-certified laboratories.
VERBATIM QUESTION: IMPLICIT
VERBATIM ANSWER: So as discussed in the previous town hall meeting, the COVID test policy guidance, as well as the FAQs on our website state, that unless and until an EUA is issued that authorize additional testing environments for a specific test under CLIA, use of that test is limited to laboratories certified to perform high complexity testing, including testing at the point of care when the site is covered by the laboratory's CLIA certificate for high complexity testing. This applies both to new tests and unauthorized modifications. So, yes, while the modification policy for commercial manufacturers of diagnostic tests provides for developers to implement modifications where they're still under FDA review, the implementation is limited to high complexity CLIA-certified laboratories.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: CLIA compliance, EUA modifications, High complexity labs
REVIEW FLAG: False

QA Block 5-7
CLARIFIED QUESTION: Are there specific criteria that an infield correction must meet under the current EUA policies?
CLARIFIED ANSWER: Infield corrections for EUA-authorized tests must adhere to policies limiting them to high complexity CLIA-certified labs until fully approved by the FDA.
VERBATIM QUESTION: Are there specific criteria that an infield correction must meet under the current EUA policies?
VERBATIM ANSWER: So this question does reflect our policy. And I did mention this policy relative to the infield correction that Abbott Molecular is making for their Alinity m system for the SARS-only test and their SARS panel test. So as discussed in the previous town hall meeting, the COVID test policy guidance, as well as the FAQs on our website state, that unless and until an EUA is issued that authorize additional testing environments for a specific test under CLIA, use of that test is limited to laboratories certified to perform high complexity testing, including testing at the point of care when the site is covered by the laboratory's CLIA certificate for high complexity testing. This applies both to new tests and unauthorized modifications. So, yes, while the modification policy for commercial manufacturers of diagnostic tests provides for developers to implement modifications where they're still under FDA review, the implementation is limited to high complexity CLIA-certified laboratories.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA policies, infield corrections, high complexity CLIA-certified labs
REVIEW FLAG: False


#### 6. Implementing Changes in Diagnostic Studies During Clinical Trials

QA Block 6-1
CLARIFIED QUESTION: If we want to implement changes to our devices and test kits, do we need to complete our current original study design, prospectively collecting 30 positives and 30 negatives, before starting a new trial with the updated device designs?
CLARIFIED ANSWER: The FDA expects you to complete your commitments for the currently authorized device before making changes, as these commitments are tied to its authorization. It may be possible to test both the current and new devices in a combined study but ensure an unbiased approach approved by the FDA reviewer.
VERBATIM QUESTION: If we want to implement changes to our devices and test kits, do we need to complete our current original study design, prospectively collecting 30 positives and 30 negatives, before starting a new trial with the updated device designs?
VERBATIM ANSWER: So any commitments made for that device are important to complete. And that's because patients have been tested with that device. And the condition of authorization for that was prescribed. And if there were to be any issues with the device, as it was for your first EUA submission, we would want to know that. So that's a commitment that your firm made at the time of authorization. And we do expect you to complete that commitment. You may be able, through an innovative study design, test both devices at the same time. But not to have any bias, I suggest you run that study, the combined study design, through our FDA review staff, your reviewer, perhaps, that was used for the initial device, to get their input before starting, just to make sure you're doing this in an unbiased manner.
SPEAKER QUESTION: Rachel Liang
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Device testing protocols, Study commitments, FDA study bias review
REVIEW FLAG: False

QA Block 6-2
CLARIFIED QUESTION: Can we terminate our study prematurely and start a new study design with the new device design?
CLARIFIED ANSWER: The FDA requires you to complete commitments for your initial device since patients have been tested with it and the conditions of authorization were prescribed. An innovative study design could allow for testing both devices simultaneously, but ensure the approach is unbiased and discussed with FDA reviewers.
VERBATIM QUESTION: Can we terminate our study prematurely and start a new study design with the new device design?
VERBATIM ANSWER: So any commitments made for that device are important to complete. And that's because patients have been tested with that device. And the condition of authorization for that was prescribed. And if there were to be any issues with the device, as it was for your first EUA submission, we would want to know that. So that's a commitment that your firm made at the time of authorization. And we do expect you to complete that commitment. You may be able, through an innovative study design, test both devices at the same time. But not to have any bias, I suggest you run that study, the combined study design, through our FDA review staff, your reviewer, perhaps, that was used for the initial device, to get their input before starting, just to make sure you're doing this in an unbiased manner.
SPEAKER QUESTION: Rachel Liang
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: study termination, device design updates, regulatory compliance
REVIEW FLAG: False

QA Block 6-3
CLARIFIED QUESTION: Would it be possible to start this new study design at the same study site, or do we need to look for a new study site to conduct this repeat validation study?
CLARIFIED ANSWER: The same study sites can be used, either after the first study is complete or simultaneously, provided the process ensures unbiased results. Consult with the FDA reviewer for specific study details.
VERBATIM QUESTION: Would it be possible to start this new study design at the same study site, or do we need to look for a new study site to conduct this repeat validation study?
VERBATIM ANSWER: The same sites could be used, and they could be used. You could begin the new study after you finish the first, but maybe a little bit cleaner, easier for the study site to understand and not get confused. But again, if you were to want to do this, finish the commitment for the original device and start validation for the same device at the same time, maybe even on the same patients. There's no prohibition against doing that. We would just want to make sure that you're doing in a manner that is unbiased towards the new devices. And obviously, you might get three swabs. I don't know the details of your procedure, whether it's a direct swab or goes into some sort of buffer and if the buffer is the same between the two devices. If you use a buffer first and the buffer is the same between the two devices, then you want the tests done in a manner in which the person performing the test doesn't know the result for the other sample. So I mean, if they start the process for both at the same time before any one results out, then you could eliminate on this bias. But these are the details that are best had in discussion with your reviewer.
SPEAKER QUESTION: Rachel Liang
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: study site selection, validation study design, bias mitigation
REVIEW FLAG: False

QA Block 6-4
CLARIFIED QUESTION: What is the recommended approach to testing multiple device designs in a clinical trial to avoid bias?
CLARIFIED ANSWER: The FDA recommends testing both device designs simultaneously in an unbiased manner. This should involve consulting with FDA reviewers to ensure the study is properly structured.
VERBATIM QUESTION: What is the recommended approach to testing multiple device designs in a clinical trial to avoid bias?
VERBATIM ANSWER: You may be able, through an innovative study design, test both devices at the same time. But not to have any bias, I suggest you run that study, the combined study design, through our FDA review staff, your reviewer, perhaps, that was used for the initial device, to get their input before starting, just to make sure you're doing this in an unbiased manner.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: unbiased clinical study, testing multiple device designs, FDA guidance
REVIEW FLAG: False

QA Block 6-5
CLARIFIED QUESTION: Can we use the same clinical site staff and subjects for testing both the original and updated device designs?
CLARIFIED ANSWER: Yes, the same clinical site staff and subjects can be used to test both the original and updated device designs, provided they are willing to participate.
VERBATIM QUESTION: Can we use the same clinical site staff and subjects for testing both the original and updated device designs?
VERBATIM ANSWER: Oh, yeah, you can do those in parallel. And you could even-- I don't know how complex your study design iseven consider and testing with both devices, if your subjects are willing to do that and your clinical site staff are willing to do that.
SPEAKER QUESTION: Rachel Liang
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: clinical site staff, device design testing, parallel study design
REVIEW FLAG: False

QA Block 6-6
CLARIFIED QUESTION: Are there specific procedures for using buffers common to multiple devices in order to ensure unbiased results?
CLARIFIED ANSWER: If a buffer is used and is the same between devices, tests should be conducted so the person performing the test does not know the result of the other sample to avoid bias. FDA recommends discussing specifics with your reviewer.
VERBATIM QUESTION: Are there specific procedures for using buffers common to multiple devices in order to ensure unbiased results?
VERBATIM ANSWER: If you use a buffer first and the buffer is the same between the two devices, then you want the tests done in a manner in which the person performing the test doesn't know the result for the other sample. So I mean, if they start the process for both at the same time before any one results out, then you could eliminate on this bias. But these are the details that are best had in discussion with your reviewer.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: buffers for unbiased testing, clinical test design
REVIEW FLAG: False

QA Block 6-7
CLARIFIED QUESTION: What precautions should be taken when testing multiple samples from the same patient to prevent bias?
CLARIFIED ANSWER: Testing should be done in a way that eliminates bias, such as ensuring the tester is unaware of the results of other samples and conducting tests simultaneously. Consult the FDA reviewer for study-specific details.
VERBATIM QUESTION: What precautions should be taken when testing multiple samples from the same patient to prevent bias?
VERBATIM ANSWER: We would just want to make sure that you're doing in a manner that is unbiased towards the new devices. And obviously, you might get three swabs. I don't know the details of your procedure, whether it's a direct swab or goes into some sort of buffer and if the buffer is the same between the two devices. If you use a buffer first and the buffer is the same between the two devices, then you want the tests done in a manner in which the person performing the test doesn't know the result for the other sample. So I mean, if they start the process for both at the same time before any one results out, then you could eliminate on this bias. But these are the details that are best had in discussion with your reviewer.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Precautions for avoiding bias, Testing multiple samples, FDA guidance
REVIEW FLAG: False

QA Block 6-8
CLARIFIED QUESTION: How should developers proceed in validating changes to a device while fulfilling original EUA commitments?
CLARIFIED ANSWER: Developers must fulfill original EUA commitments as these are tied to patient safety and device authorization. They may validate changes by conducting concurrent studies for both the original and updated devices, ensuring the process is unbiased. FDA recommends consulting their review staff for guidance.
VERBATIM QUESTION: How should developers proceed in validating changes to a device while fulfilling original EUA commitments?
VERBATIM ANSWER: So any commitments made for that device are important to complete. And that's because patients have been tested with that device. And the condition of authorization for that was prescribed. And if there were to be any issues with the device, as it was for your first EUA submission, we would want to know that. So that's a commitment that your firm made at the time of authorization. And we do expect you to complete that commitment. You may be able, through an innovative study design, test both devices at the same time. But not to have any bias, I suggest you run that study, the combined study design, through our FDA review staff, your reviewer, perhaps, that was used for the initial device, to get their input before starting, just to make sure you're doing this in an unbiased manner.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA commitments, Validation of updates, Unbiased study design
REVIEW FLAG: False


#### 7. Prescription vs OTC Multi-Analyte Tests: Key Considerations

QA Block 7-1
CLARIFIED QUESTION: Can you clarify where and how healthcare providers would be involved with multi-analyte panel tests, such as whether they are just writing a prescription for the test or also being involved during result interpretation?
CLARIFIED ANSWER: Healthcare providers are involved by writing the prescription for multi-analyte tests. Patients are encouraged to report results to clinicians and discuss them. Provider-patient interaction is recommended to help with result interpretation.
VERBATIM QUESTION: Can you clarify where and how healthcare providers would be involved with multi-analyte panel tests, such as whether they are just writing a prescription for the test or also being involved during result interpretation?
VERBATIM ANSWER: You can look at the home prescription tests that we've already authorized. There's still some on the FDA website. You can look at all the labeling, the IFU, the instructions, what we recommend. So it starts with a prescription written by the health care provider. And then the patient can get the test. And that may even be something that is done well before a patient has any symptoms or any need to test so that they have the test on hand. When they complete the testing, then they're encouraged to report those results to their clinician and discuss those results with them. That's the additional mitigation that we're asking for in that situation. But again, I think we still have a couple that haven't moved to OTC in the home and that are prescription pills, so you can see the labeling and the interaction between patient and clinician that we recommend.
SPEAKER QUESTION: Ling Koh
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: healthcare provider role, multi-analyte panel tests, result interpretation
REVIEW FLAG: False

QA Block 7-2
CLARIFIED QUESTION: Even for a multi-analyte panel that tests for both flu and SARS-CoV-2, can the same recommendations for flu-exempt tests be applied?
CLARIFIED ANSWER: The FDA confirmed that the same recommendations for flu-exempt tests can apply to multi-analyte panels testing for both flu and SARS-CoV-2.
VERBATIM QUESTION: Even for a multi-analyte panel that tests for both flu and SARS-CoV-2, can the same recommendations for flu-exempt tests be applied?
VERBATIM ANSWER: Yes.
SPEAKER QUESTION: Ling Koh
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Multi-analyte panel, Flu-exempt tests, FDA recommendations
REVIEW FLAG: False

QA Block 7-3
CLARIFIED QUESTION: If a robust usability study demonstrates high user comprehension for flu and SARS-CoV-2 test results, could that reopen discussions about OTC authorization instead of prescription-only use?
CLARIFIED ANSWER: FDA is open-minded but has concerns about OTC use for asymptomatic flu or RSV testing due to unclear implications of results. EUA authorizations primarily cover SARS-CoV-2, with flexibility for symptomatic cases of other analytes, but asymptomatic cases require physician involvement.
VERBATIM QUESTION: If a robust usability study demonstrates high user comprehension for flu and SARS-CoV-2 test results, could that reopen discussions about OTC authorization instead of prescription-only use?
VERBATIM ANSWER: Well, we always remain open-minded. But our concerns go to testing somebody who's asymptomatic for flu or RSV. We just don't know what that means in those two populations and what they should do with that information. And so there could be false positives, could be true positives. And we just don't understand in an asymptomatic population, in particular, when we give an OTC authorization, it's typically a situation to use that for screening for SARS-CoV-2 given that there's so many asymptomatic positives out there. And so the EUA authorities cover SARS. They don't necessarily cover any other analytes. We made some flexibility here to allow other analytes because they're certainly in the differential diagnosis if you have symptoms. But they wouldn't necessarily be in the differential diagnosis if you didn't have symptoms. And so if a patient is asymptomatic and gets a positive for flu or RSV, we want them to have a physician or clinician contact to try to understand what that means and know what to do with that.
SPEAKER QUESTION: Ling Koh
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: OTC test authorization, Usability studies, HCP involvement
REVIEW FLAG: False

QA Block 7-4
CLARIFIED QUESTION: When you say 'physician contact,' does it mean that the result has to go through a healthcare provider before release, or is it just encouraged that an HCP is available to assist upon receiving results?
CLARIFIED ANSWER: FDA clarifies that physician contact may depend on the test type. For home collection devices, a physician may review results before release, whereas in home tests, patients see their results first. FDA emphasizes the importance of patient access to healthcare professionals for understanding results.
VERBATIM QUESTION: When you say 'physician contact,' does it mean that the result has to go through a healthcare provider before release, or is it just encouraged that an HCP is available to assist upon receiving results?
VERBATIM ANSWER: So it depends. I mean, there's home collection devices that physicians may want to look at the results before they release it to the patient. If it's a home test situation, the patients are going to see their results there before the physician or clinician does. And so we want to have there be a relationship between the patient and their health care provider established so that we know that that patient has access to a health care professional to help understand the results.
SPEAKER QUESTION: Ling Koh
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Physician contact, Home test result processing, Healthcare provider involvement
REVIEW FLAG: False

QA Block 7-5
CLARIFIED QUESTION: What guidance does the FDA provide on labeling and instructions for home-use prescription tests for COVID-19 and flu?
CLARIFIED ANSWER: FDA guidance for home-use prescription tests includes labeling, instructions, and prescription details. Patients should report and discuss the test results with their clinician, establishing a connection for further support.
VERBATIM QUESTION: What guidance does the FDA provide on labeling and instructions for home-use prescription tests for COVID-19 and flu?
VERBATIM ANSWER: You can look at the home prescription tests that we've already authorized. There's still some on the FDA website. You can look at all the labeling, the IFU, the instructions, what we recommend. So it starts with a prescription written by the health care provider. And then the patient can get the test. And that may even be something that is done well before a patient has any symptoms or any need to test so that they have the test on hand. When they complete the testing, then they're encouraged to report those results to their clinician and discuss those results with them. That's the additional mitigation that we're asking for in that situation. But again, I think we still have a couple that haven't moved to OTC in the home and that are prescription pills, so you can see the labeling and the interaction between patient and clinician that we recommend.
SPEAKER QUESTION: Ling Koh
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: labeling for home-use tests, patient-clinician interaction, prescription procedures
REVIEW FLAG: False

QA Block 7-6
CLARIFIED QUESTION: Under what conditions should patients report their home test results to a clinician, and what role does clinical consultation play in interpreting these results?
CLARIFIED ANSWER: Patients should report home test results to their clinician and engage in discussion to understand the result and take appropriate steps.
VERBATIM QUESTION: Under what conditions should patients report their home test results to a clinician, and what role does clinical consultation play in interpreting these results?
VERBATIM ANSWER: When they complete the testing, then they're encouraged to report those results to their clinician and discuss those results with them. That's the additional mitigation that we're asking for in that situation.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: reporting home test results, clinical consultation
REVIEW FLAG: False

QA Block 7-7
CLARIFIED QUESTION: What additional mitigations does the FDA recommend for prescription authorization of home tests?
CLARIFIED ANSWER: The FDA recommends starting with a prescription written by a healthcare provider, the patient obtaining the test, and reporting and discussing results with their clinician after completing the test as an additional mitigation.
VERBATIM QUESTION: What additional mitigations does the FDA recommend for prescription authorization of home tests?
VERBATIM ANSWER: So it starts with a prescription written by the health care provider. And then the patient can get the test. And that may even be something that is done well before a patient has any symptoms or any need to test so that they have the test on hand. When they complete the testing, then they're encouraged to report those results to their clinician and discuss those results with them. That's the additional mitigation that we're asking for in that situation.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Prescription home tests, FDA mitigation recommendations, Patient-clinician interaction
REVIEW FLAG: False

QA Block 7-8
CLARIFIED QUESTION: Are there differences in guidance for labeling in home-use scenarios that involve prescription versus OTC tests?
CLARIFIED ANSWER: FDA outlines that home-use tests with prescription labeling follow specific guidance that includes requiring a prescription, encouraging patient-clinician result discussions, and detailing patient-clinician interactions on the labeling. OTC tests differ as they often lack this requirement for a clinician relationship.
VERBATIM QUESTION: Are there differences in guidance for labeling in home-use scenarios that involve prescription versus OTC tests?
VERBATIM ANSWER: You can look at the home prescription tests that we've already authorized. There's still some on the FDA website. You can look at all the labeling, the IFU, the instructions, what we recommend. So it starts with a prescription written by the health care provider. And then the patient can get the test. And that may even be something that is done well before a patient has any symptoms or any need to test so that they have the test on hand. When they complete the testing, then they're encouraged to report those results to their clinician and discuss those results with them. That's the additional mitigation that we're asking for in that situation. But again, I think we still have a couple that haven't moved to OTC in the home and that are prescription pills, so you can see the labeling and the interaction between patient and clinician that we recommend.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Labeling guidance for prescription vs OTC, Home-use diagnostics, Patient-clinician interaction
REVIEW FLAG: False

QA Block 7-9
CLARIFIED QUESTION: How does the FDA view the inclusion of other analytes like flu or RSV in differential diagnosis for asymptomatic versus symptomatic individuals in the context of EUA?
CLARIFIED ANSWER: The FDA acknowledges flexibility for including other analytes like flu or RSV in tests, but emphasizes that these analytes are relevant to differential diagnoses only for symptomatic individuals. For asymptomatic individuals, the meaning of flu or RSV results is unclear, necessitating physician involvement.
VERBATIM QUESTION: How does the FDA view the inclusion of other analytes like flu or RSV in differential diagnosis for asymptomatic versus symptomatic individuals in the context of EUA?
VERBATIM ANSWER: Well, we always remain open-minded. But our concerns go to testing somebody who's asymptomatic for flu or RSV. We just don't know what that means in those two populations and what they should do with that information. And so there could be false positives, could be true positives. And we just don't understand in an asymptomatic population, in particular, when we give an OTC authorization, it's typically a situation to use that for screening for SARS-CoV-2 given that there's so many asymptomatic positives out there. And so the EUA authorities cover SARS. They don't necessarily cover any other analytes. We made some flexibility here to allow other analytes because they're certainly in the differential diagnosis if you have symptoms. But they wouldn't necessarily be in the differential diagnosis if you didn't have symptoms. And so if a patient is asymptomatic and gets a positive for flu or RSV, we want them to have a physician or clinician contact to try to understand what that means and know what to do with that.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA for multi-analyte panels, Symptomatic vs asymptomatic testing, Physician involvement
REVIEW FLAG: False

QA Block 7-10
CLARIFIED QUESTION: What specific clinician and patient interaction or access requirements must be established in home test approval considerations?
CLARIFIED ANSWER: FDA requires a relationship between patients and healthcare providers to ensure professional access for interpreting and acting on test results, with patients typically seeing results before clinicians in home test scenarios.
VERBATIM QUESTION: What specific clinician and patient interaction or access requirements must be established in home test approval considerations?
VERBATIM ANSWER: So it depends. I mean, there's home collection devices that physicians may want to look at the results before they release it to the patient. If it's a home test situation, the patients are going to see their results there before the physician or clinician does. And so we want to have there be a relationship between the patient and their health care provider established so that we know that that patient has access to a health care professional to help understand the results.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Home test approval, Clinician-patient interaction, Test result interpretation
REVIEW FLAG: False


#### 8. Clarification on Confirmed Positives and FDA Communication Response Time

QA Block 8-1
CLARIFIED QUESTION: For confirming positive results in the clinical agreement section for serology assays, can an FDA EUA antigen or rapid test, such as the BinaxNOW, be used as a positive confirmatory test?
CLARIFIED ANSWER: FDA cannot address this question during the call as it is too detailed or case-specific. They recommend contacting the CDRH EUA Templates email or reaching out to an assigned reviewer.
VERBATIM QUESTION: For confirming positive results in the clinical agreement section for serology assays, can an FDA EUA antigen or rapid test, such as the BinaxNOW, be used as a positive confirmatory test?
VERBATIM ANSWER: So I neglected to read a disclaimer at the beginning of the question that we went over that were received prior to the call. And this is true for every week. So we do receive some questions that are a little too detailed or test- or case-specific that we will not address on the call. And so I forgot to do that. So that was the case for your question. So I do recommend that you reach out to FDA staff through the CDRH EUA Templates email address. Or if you already have a reviewer assigned, to reach out to them to engage them in this conversation. I'm not going to be able to go over that question today.
SPEAKER QUESTION: Julio Herrera
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: serology assay validation, EUA-authorized tests, FDA support process
REVIEW FLAG: False

QA Block 8-2
CLARIFIED QUESTION: Are vaccinated individuals, who are four to six months past their last dose and are now sending a confirmatory positive result, eligible to be considered confirmed positives for the clinical agreement or usability?
CLARIFIED ANSWER: The FDA cannot address this test-specific inquiry during the call and recommends contacting the staff via the CDRH EUA Templates email or assigned reviewer.
VERBATIM QUESTION: Are vaccinated individuals, who are four to six months past their last dose and are now sending a confirmatory positive result, eligible to be considered confirmed positives for the clinical agreement or usability?
VERBATIM ANSWER: So I neglected to read a disclaimer at the beginning of the question that we went over that were received prior to the call. And this is true for every week. So we do receive some questions that are a little too detailed or test- or case-specific that we will not address on the call. And so I forgot to do that. So that was the case for your question. So I do recommend that you reach out to FDA staff through the CDRH EUA Templates email address. Or if you already have a reviewer assigned, to reach out to them to engage them in this conversation. I'm not going to be able to go over that question today.
SPEAKER QUESTION: Julio Herrera
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: vaccinated individuals as confirmed positives, clinical agreement, FDA guidance
REVIEW FLAG: False

QA Block 8-4
CLARIFIED QUESTION: What should developers do if a test- or case-specific question cannot be addressed during the FDA Town Hall meeting?
CLARIFIED ANSWER: For test- or case-specific questions that cannot be addressed during the FDA Town Hall meeting, developers should contact FDA staff through the CDRH EUA Templates email or engage with an assigned reviewer.
VERBATIM QUESTION: What should developers do if a test- or case-specific question cannot be addressed during the FDA Town Hall meeting?
VERBATIM ANSWER: So we do receive some questions that are a little too detailed or test- or case-specific that we will not address on the call. And so I forgot to do that. So that was the case for your question. So I do recommend that you reach out to FDA staff through the CDRH EUA Templates email address. Or if you already have a reviewer assigned, to reach out to them to engage them in this conversation.
SPEAKER QUESTION: Julio Herrera
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Test-specific inquiries, Contacting FDA, Town Hall limitations
REVIEW FLAG: False

QA Block 8-5
CLARIFIED QUESTION: Who should developers contact if they have already been assigned a reviewer but still need additional clarification on their submission?
CLARIFIED ANSWER: Developers assigned a reviewer should contact that reviewer directly for additional clarification on their submission.
VERBATIM QUESTION: Who should developers contact if they have already been assigned a reviewer but still need additional clarification on their submission?
VERBATIM ANSWER: Or if you already have a reviewer assigned, to reach out to them to engage them in this conversation.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: developer communication, submission clarification
REVIEW FLAG: False

QA Block 8-6
CLARIFIED QUESTION: Is there a specific protocol to follow if developers have not received a timely response from the CDRH EUA Templates email address?
CLARIFIED ANSWER: Developers can send another email to the CDRH EUA Templates address after a couple of weeks and request contact with Toby.
VERBATIM QUESTION: Is there a specific protocol to follow if developers have not received a timely response from the CDRH EUA Templates email address?
VERBATIM ANSWER: If it's been more than a couple of weeks, you can go ahead and send another email to the Templates email address and ask them, in this case, to contact Toby.
SPEAKER QUESTION: Julio Herrera
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: FDA response protocol, CDRH EUA Templates email
REVIEW FLAG: False


#### 9. EUA Submission vs. Pre-EUA for FDA Approval

QA Block 9-2
CLARIFIED QUESTION: Which submission approach do you recommend: submitting a pre-EUA first or submitting the EUA directly?
CLARIFIED ANSWER: FDA recommends submitting the EUA directly for routine tests using established templates, as it saves time and carries minimal risk if following standard guidelines.
VERBATIM QUESTION: Which submission approach do you recommend: submitting a pre-EUA first or submitting the EUA directly?
VERBATIM ANSWER: Yeah, so for most EUA submissions today for routine sort of assay tests, we've got templates for all recommendations for all the studies. And there are lots of authorizations for all these common types of tests. So I really don't believe there's any need for pre-EUA and would not recommend that pre-EUAs be used in those circumstances, but that you go right ahead and do your EUA. And that will save a lot of time. There is some risks, as always. But if you're doing exactly what others have done in the same manner, and according to our template, the risks are very, very small.
SPEAKER QUESTION: Tianyang Liu
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: submission approach, EUA process, pre-EUA guidance
REVIEW FLAG: False

QA Block 9-3
CLARIFIED QUESTION: If a submission protocol is really good, could it take longer for the FDA team to respond initially but proceed quickly after receiving official feedback?
CLARIFIED ANSWER: The FDA has a backlog of applications and prioritizes EUAs for standard tests over pre-EUAs, especially when tests follow templates and established protocols. Pre-EUAs should be reserved for novel cases.
VERBATIM QUESTION: If a submission protocol is really good, could it take longer for the FDA team to respond initially but proceed quickly after receiving official feedback?
VERBATIM ANSWER: So, we are still receiving so many applications and still have a backlog. And we're trying to get through everything. And again, it's why I don't recommend a pre-EUA if you're just fine with standard recommendations that the FDA makes for standard devices. People should reserve the pre- EUA for something novel, something new, something that we haven't discussed on this town hall, something that isn't in the templates, something there isn't a template for. That's where you get the most bang for the buck on the pre-EUA. We do make some recommendations about pre-EUA. But that's not global and it's very specific and is trying to manage the workflow that we have. So we have a lot of EUAs in house. And when we have an EUA in house, where perhaps all the studies were done and the tests can be authorized, it seems a little bit more important for us to review that than a pre-EUA for something that's very standard. But we're trying to get to all the work. It's just a lot of work.
SPEAKER QUESTION: Tianyang Liu
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: FDA response time, EUA prioritization, Pre-EUA recommendations
REVIEW FLAG: False

QA Block 9-4
CLARIFIED QUESTION: What are the risks associated with bypassing the pre-EUA process if developers follow existing templates?
CLARIFIED ANSWER: The FDA advises bypassing pre-EUA for routine assay tests with established templates, as risks are minimal when following standard procedures.
VERBATIM QUESTION: What are the risks associated with bypassing the pre-EUA process if developers follow existing templates?
VERBATIM ANSWER: Yeah, so for most EUA submissions today for routine sort of assay tests, we've got templates for all recommendations for all the studies. And there are lots of authorizations for all these common types of tests. So I really don't believe there's any need for pre-EUA and would not recommend that pre-EUAs be used in those circumstances, but that you go right ahead and do your EUA. And that will save a lot of time. There is some risks, as always. But if you're doing exactly what others have done in the same manner, and according to our template, the risks are very, very small.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Pre-EUA vs EUA, FDA templates, Risk assessment
REVIEW FLAG: False

QA Block 9-5
CLARIFIED QUESTION: Under what circumstances is submitting a pre-EUA beneficial?
CLARIFIED ANSWER: Submitting a pre-EUA is beneficial when the test is novel, not covered in templates, or something not previously discussed in FDA guidance.
VERBATIM QUESTION: Under what circumstances is submitting a pre-EUA beneficial?
VERBATIM ANSWER: People should reserve the pre-EUA for something novel, something new, something that we haven't discussed on this town hall, something that isn't in the templates, something there isn't a template for. That's where you get the most bang for the buck on the pre-EUA.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: pre-EUA conditions, novel diagnostic tests
REVIEW FLAG: False

QA Block 9-6
CLARIFIED QUESTION: Are there FDA recommendations for using a pre-EUA specifically for novel or non-template-based submissions?
CLARIFIED ANSWER: FDA recommends reserving pre-EUA submissions for novel or non-template-based tests where it can provide the most value. Pre-EUA submissions are not recommended for standard devices following established templates.
VERBATIM QUESTION: Are there FDA recommendations for using a pre-EUA specifically for novel or non-template-based submissions?
VERBATIM ANSWER: People should reserve the pre- EUA for something novel, something new, something that we haven't discussed on this town hall, something that isn't in the templates, something there isn't a template for. That's where you get the most bang for the buck on the pre-EUA. We do make some recommendations about pre-EUA. But that's not global and it's very specific and is trying to manage the workflow that we have.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: pre-EUA usage, novel diagnostics, FDA recommendations
REVIEW FLAG: False

QA Block 9-8
CLARIFIED QUESTION: How does the FDA determine what qualifies as something 'novel' for prioritizing pre-EUAs?
CLARIFIED ANSWER: The FDA prioritizes pre-EUAs for novel or new items not covered in existing town halls or templates and without available templates.
VERBATIM QUESTION: How does the FDA determine what qualifies as something 'novel' for prioritizing pre-EUAs?
VERBATIM ANSWER: People should reserve the pre-EUA for something novel, something new, something that we haven't discussed on this town hall, something that isn't in the templates, something there isn't a template for. That's where you get the most bang for the buck on the pre-EUA.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: pre-EUA process, novel devices, FDA prioritization
REVIEW FLAG: False

QA Block 9-9
CLARIFIED QUESTION: What workflow management practices does the FDA use to handle the EUA and pre-EUA submission backlog?
CLARIFIED ANSWER: The FDA is managing a large backlog of EUA applications and prioritizes reviewing complete EUA submissions over pre-EUA submissions, especially for standard tests. Pre-EUA submissions are recommended only for novel or unique cases.
VERBATIM QUESTION: What workflow management practices does the FDA use to handle the EUA and pre-EUA submission backlog?
VERBATIM ANSWER: So, we are still receiving so many applications and still have a backlog. And we're trying to get through everything. And again, it's why I don't recommend a pre-EUA if you're just fine with standard recommendations that the FDA makes for standard devices. People should reserve the pre- EUA for something novel, something new, something that we haven't discussed on this town hall, something that isn't in the templates, something there isn't a template for. That's where you get the most bang for the buck on the pre-EUA. We do make some recommendations about pre-EUA. But that's not global and it's very specific and is trying to manage the workflow that we have. So we have a lot of EUAs in house. And when we have an EUA in house, where perhaps all the studies were done and the tests can be authorized, it seems a little bit more important for us to review that than a pre-EUA for something that's very standard. But we're trying to get to all the work. It's just a lot of work.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA backlog, Workflow prioritization, Pre-EUA recommendations
REVIEW FLAG: False


#### 10. Saliva Specimens and Nasal Swabs in COVID Diagnostics

QA Block 10-1
CLARIFIED QUESTION: Can we now submit an EUA using just saliva specimens for approval for COVID diagnosis?
CLARIFIED ANSWER: FDA continues to require saliva tests to be validated against nasopharyngeal swabs due to performance concerns with saliva, though they are open to seeing more data.
VERBATIM QUESTION: Can we now submit an EUA using just saliva specimens for approval for COVID diagnosis?
VERBATIM ANSWER: You're not going to like my response. So we don't publish negative decisions. And we continue to see challenges with saliva tests. Saliva is an option that we provided. It's a very unique option in the world of respiratory viruses. Saliva-- we don't know, to say the performance of other virus detection-- flu, RSV. We've gotten questions about panels from saliva. And we just don't know if those viruses will work. We're open to seeing data. But I've also seen data that suggests that the viral contents in some saliva patients can be much lower than a nasal swab or a nasopharyngeal swab. So our recommendations still stand for validation of saliva tests, that it gets compared to a nasopharyngeal swab.
SPEAKER QUESTION: David States
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Saliva specimen validation, EUA submission requirements
REVIEW FLAG: False

QA Block 10-2
CLARIFIED QUESTION: Would a nasal turbinate swab be an acceptable comparison?
CLARIFIED ANSWER: The FDA has allowed mid-turbinate swabs as an acceptable comparison.
VERBATIM QUESTION: Would a nasal turbinate swab be an acceptable comparison?
VERBATIM ANSWER: We have allowed mid-turbinate swabs. That's correct.
SPEAKER QUESTION: David States
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: nasal turbinate swabs, EUA specimen comparison
REVIEW FLAG: False

QA Block 10-3
CLARIFIED QUESTION: What is the FDA's current stance on the performance of saliva-based diagnostics for detecting viruses beyond COVID-19, such as flu or RSV?
CLARIFIED ANSWER: The FDA acknowledges saliva as an option for testing respiratory viruses but does not have sufficient data on its effectiveness for detecting flu or RSV. Saliva tests should still be validated against nasopharyngeal swabs.
VERBATIM QUESTION: What is the FDA's current stance on the performance of saliva-based diagnostics for detecting viruses beyond COVID-19, such as flu or RSV?
VERBATIM ANSWER: Saliva is an option that we provided. It's a very unique option in the world of respiratory viruses. Saliva-- we don't know, to say the performance of other virus detection-- flu, RSV. We've gotten questions about panels from saliva. And we just don't know if those viruses will work. We're open to seeing data. But I've also seen data that suggests that the viral contents in some saliva patients can be much lower than a nasal swab or a nasopharyngeal swab. So our recommendations still stand for validation of saliva tests, that it gets compared to a nasopharyngeal swab.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: saliva-based diagnostics, flu and RSV testing, validation requirements
REVIEW FLAG: False

QA Block 10-4
CLARIFIED QUESTION: Does the FDA require any additional data for saliva-based diagnostics to ensure accuracy across different respiratory viruses?
CLARIFIED ANSWER: FDA states that saliva is a unique sample type for respiratory viruses but requires further data to establish its performance for detecting flu, RSV, or other viruses. FDA continues to recommend comparing saliva-based diagnostics to nasopharyngeal swabs for validation.
VERBATIM QUESTION: Does the FDA require any additional data for saliva-based diagnostics to ensure accuracy across different respiratory viruses?
VERBATIM ANSWER: Saliva is an option that we provided. It's a very unique option in the world of respiratory viruses. Saliva-- we don't know, to say the performance of other virus detection-- flu, RSV. We've gotten questions about panels from saliva. And we just don't know if those viruses will work. We're open to seeing data. But I've also seen data that suggests that the viral contents in some saliva patients can be much lower than a nasal swab or a nasopharyngeal swab. So our recommendations still stand for validation of saliva tests, that it gets compared to a nasopharyngeal swab.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: saliva-based diagnostic validation, respiratory virus detection, comparison with nasopharyngeal swabs
REVIEW FLAG: False

QA Block 10-5
CLARIFIED QUESTION: How should developers interpret data indicating lower viral load in saliva specimens compared to nasal or nasopharyngeal swabs when validating tests?
CLARIFIED ANSWER: The FDA recommends comparing saliva-based tests to nasopharyngeal swabs for validation as data shows saliva specimens often have lower viral loads.
VERBATIM QUESTION: How should developers interpret data indicating lower viral load in saliva specimens compared to nasal or nasopharyngeal swabs when validating tests?
VERBATIM ANSWER: Saliva is an option that we provided. It's a very unique option in the world of respiratory viruses. Saliva-- we don't know, to say the performance of other virus detection-- flu, RSV. We've gotten questions about panels from saliva. And we just don't know if those viruses will work. We're open to seeing data. But I've also seen data that suggests that the viral contents in some saliva patients can be much lower than a nasal swab or a nasopharyngeal swab. So our recommendations still stand for validation of saliva tests, that it gets compared to a nasopharyngeal swab.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: saliva vs. nasal swabs, viral load comparison, test validation
REVIEW FLAG: False

QA Block 10-6
CLARIFIED QUESTION: Has the FDA observed substantial performance variability in saliva-based diagnostic tests submitted for EUA?
CLARIFIED ANSWER: The FDA continues to see challenges with saliva-based diagnostic tests, with variability in performance and lower viral contents compared to other sample types like swabs.
VERBATIM QUESTION: Has the FDA observed substantial performance variability in saliva-based diagnostic tests submitted for EUA?
VERBATIM ANSWER: We continue to see challenges with saliva tests. Saliva is an option that we provided. It's a very unique option in the world of respiratory viruses. Saliva-- we don't know, to say the performance of other virus detection-- flu, RSV. We've gotten questions about panels from saliva. And we just don't know if those viruses will work. We're open to seeing data. But I've also seen data that suggests that the viral contents in some saliva patients can be much lower than a nasal swab or a nasopharyngeal swab.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: saliva-based diagnostic tests, performance variability, validation requirements
REVIEW FLAG: False


#### 11. Challenges and Proposals for Rapid Test Validation Programs

QA Block 11-1
CLARIFIED QUESTION: Do you see FDA, CDC, NIH, or any organization taking a more active role in helping test developers with the validation of tests, similar to programs in countries like the UK or Germany?
CLARIFIED ANSWER: The FDA prioritizes antigen tests and quickly processes applications. A government program to validate antigen tests, similar to the serology test program, is an interesting idea and may be valuable. FDA supports the concept and will consider taking the idea back.
VERBATIM QUESTION: Do you see FDA, CDC, NIH, or any organization taking a more active role in helping test developers with the validation of tests, similar to programs in countries like the UK or Germany?
VERBATIM ANSWER: So thank you for your question. As I stated at the top of the call, antigen tests, very specifically I mentioned, if you were on the call at that time, continuing to be a top priority. And the FDA is doing its part to get through all the applications as quickly as possible and give feedback to submitters as quickly as possible. Your idea of a US government stood-up program to evaluate antigen tests is an interesting one. Of course, the FDA and NCI and CDC stood up a program for the serology test developers. And I forget the latest number on serology tests, but we authorized almost 90, if not over 90 serology tests, many of them lateral flow devices very similar to antigen tests through that program. And it's an interesting idea, and very willing to take that back. That program at the NCI was funded. And it took a lot of money to do that program. I don't know if the budget numbers are public. But I know the amount and it was not insignificant. And obviously, I would be very supportive of something like that, because an independent assessment by the US government is quite valuable. And as we found out with the serology test, and I think I've mentioned this multiple times before on this call, those tests that were submitted to NCI and were cleared by the FDA to be tested at NCI, we did an initial review of all submissions only recommended to NCI those tests that after our initial review seemed important to test. So we did eliminate from the list before NCI tested, and still something like 60% to 70% of the tests that had passed that first FDA review failed at NCI. And so this kind of program can be very helpful for challenging questions. And I think it's a really good idea and definitely will take that back.
SPEAKER QUESTION: Franco Calderon
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Test validation, Government programs, Antigen tests
REVIEW FLAG: False

QA Block 11-2
CLARIFIED QUESTION: Could the US government implement a program to evaluate and validate antigen tests similar to the established program for serology tests?
CLARIFIED ANSWER: The FDA finds the idea of a US government program to evaluate antigen tests interesting and notes the success of a similar program for serology tests, which involved significant funding and stringent initial reviews. FDA is willing to support such initiatives and will consider taking the idea back for discussion.
VERBATIM QUESTION: Could the US government implement a program to evaluate and validate antigen tests similar to the established program for serology tests?
VERBATIM ANSWER: Your idea of a US government stood-up program to evaluate antigen tests is an interesting one. Of course, the FDA and NCI and CDC stood up a program for the serology test developers. And I forget the latest number on serology tests, but we authorized almost 90, if not over 90 serology tests, many of them lateral flow devices very similar to antigen tests through that program. And it's an interesting idea, and very willing to take that back. That program at the NCI was funded. And it took a lot of money to do that program. I don't know if the budget numbers are public. But I know the amount and it was not insignificant. And obviously, I would be very supportive of something like that, because an independent assessment by the US government is quite valuable. And as we found out with the serology test, and I think I've mentioned this multiple times before on this call, those tests that were submitted to NCI and were cleared by the FDA to be tested at NCI, we did an initial review of all submissions only recommended to NCI those tests that after our initial review seemed important to test. So we did eliminate from the list before NCI tested, and still something like 60% to 70% of the tests that had passed that first FDA review failed at NCI. And so this kind of program can be very helpful for challenging questions. And I think it's a really good idea and definitely will take that back.
SPEAKER QUESTION: Franco Calderon
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: US Program for Antigen Test Evaluation, Serology Test Program Comparison, FDA Support for Independent Assessments
REVIEW FLAG: False

QA Block 11-3
CLARIFIED QUESTION: What is the FDA's current prioritization process for reviewing COVID-19 antigen test applications?
CLARIFIED ANSWER: The FDA prioritizes COVID-19 antigen tests, working to review and provide feedback on applications promptly. The idea of establishing a US government-led evaluation program for antigen tests, akin to the past approach for serology tests, is being considered.
VERBATIM QUESTION: What is the FDA's current prioritization process for reviewing COVID-19 antigen test applications?
VERBATIM ANSWER: As I stated at the top of the call, antigen tests, very specifically I mentioned, if you were on the call at that time, continuing to be a top priority. And the FDA is doing its part to get through all the applications as quickly as possible and give feedback to submitters as quickly as possible. Your idea of a US government stood-up program to evaluate antigen tests is an interesting one. Of course, the FDA and NCI and CDC stood up a program for the serology test developers. And I forget the latest number on serology tests, but we authorized almost 90, if not over 90 serology tests, many of them lateral flow devices very similar to antigen tests through that program.
SPEAKER QUESTION: Franco Calderon
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: COVID-19 antigen test review, FDA prioritization process
REVIEW FLAG: False

QA Block 11-4
CLARIFIED QUESTION: How does the FDA plan to address the economic challenges test developers face in getting their tests validated by US institutions?
CLARIFIED ANSWER: The FDA processes applications and provides feedback quickly for test validations. A government-supported program, like the past serology test program with NCI and CDC, could help address validation challenges. FDA sees value in such an initiative and may propose the idea.
VERBATIM QUESTION: How does the FDA plan to address the economic challenges test developers face in getting their tests validated by US institutions?
VERBATIM ANSWER: The FDA is doing its part to get through all the applications as quickly as possible and give feedback to submitters as quickly as possible. Your idea of a US government stood-up program to evaluate antigen tests is an interesting one. Of course, the FDA and NCI and CDC stood up a program for the serology test developers. And I forget the latest number on serology tests, but we authorized almost 90, if not over 90 serology tests, many of them lateral flow devices very similar to antigen tests through that program. And it's an interesting idea, and very willing to take that back. That program at the NCI was funded. And it took a lot of money to do that program. I don't know if the budget numbers are public. But I know the amount and it was not insignificant. And obviously, I would be very supportive of something like that, because an independent assessment by the US government is quite valuable. And as we found out with the serology test, and I think I've mentioned this multiple times before on this call, those tests that were submitted to NCI and were cleared by the FDA to be tested at NCI, we did an initial review of all submissions only recommended to NCI those tests that after our initial review seemed important to test. So we did eliminate from the list before NCI tested, and still something like 60% to 70% of the tests that had passed that first FDA review failed at NCI. And so this kind of program can be very helpful for challenging questions. And I think it's a really good idea and definitely will take that back.
SPEAKER QUESTION: Franco Calderon
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: economic challenges for test validation, potential government-supported programs, FDA review process
REVIEW FLAG: False

QA Block 11-5
CLARIFIED QUESTION: Could a government-led funding program make the antigen test evaluation process more accessible to test developers?
CLARIFIED ANSWER: FDA is open to the idea of a government-funded antigen test evaluation program similar to the serology test program, which demonstrated value through independent assessments despite high costs.
VERBATIM QUESTION: Could a government-led funding program make the antigen test evaluation process more accessible to test developers?
VERBATIM ANSWER: Your idea of a US government stood-up program to evaluate antigen tests is an interesting one. Of course, the FDA and NCI and CDC stood up a program for the serology test developers. And I forget the latest number on serology tests, but we authorized almost 90, if not over 90 serology tests, many of them lateral flow devices very similar to antigen tests through that program. And it's an interesting idea, and very willing to take that back. That program at the NCI was funded. And it took a lot of money to do that program. I don't know if the budget numbers are public. But I know the amount and it was not insignificant. And obviously, I would be very supportive of something like that, because an independent assessment by the US government is quite valuable. And as we found out with the serology test, and I think I've mentioned this multiple times before on this call, those tests that were submitted to NCI and were cleared by the FDA to be tested at NCI, we did an initial review of all submissions only recommended to NCI those tests that after our initial review seemed important to test. So we did eliminate from the list before NCI tested, and still something like 60% to 70% of the tests that had passed that first FDA review failed at NCI. And so this kind of program can be very helpful for challenging questions. And I think it's a really good idea and definitely will take that back.
SPEAKER QUESTION: Franco Calderon
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Government funding for antigen tests, Test evaluation programs, Public health impact
REVIEW FLAG: False

QA Block 11-6
CLARIFIED QUESTION: How does the FDA's initial review process determine which tests are forwarded to NCI for evaluation?
CLARIFIED ANSWER: The FDA conducts an initial review of submissions and forwards only those tests deemed important to evaluate to the NCI, although 60% to 70% of initially approved tests still fail NCI evaluation.
VERBATIM QUESTION: How does the FDA's initial review process determine which tests are forwarded to NCI for evaluation?
VERBATIM ANSWER: And as we found out with the serology test, and I think I've mentioned this multiple times before on this call, those tests that were submitted to NCI and were cleared by the FDA to be tested at NCI, we did an initial review of all submissions only recommended to NCI those tests that after our initial review seemed important to test. So we did eliminate from the list before NCI tested, and still something like 60% to 70% of the tests that had passed that first FDA review failed at NCI.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: FDA review process, NCI test evaluation, test prioritization
REVIEW FLAG: False

QA Block 11-7
CLARIFIED QUESTION: What specific lessons from the serology evaluation program could be applied to antigen test evaluations?
CLARIFIED ANSWER: The serology evaluation program showed that independent assessments by the US government, like those involving the FDA, NCI, and CDC, can be valuable for evaluating tests, as many tests failed despite initial FDA reviews. Applying similar processes and funding for antigen test evaluations could be impactful.
VERBATIM QUESTION: What specific lessons from the serology evaluation program could be applied to antigen test evaluations?
VERBATIM ANSWER: Of course, the FDA and NCI and CDC stood up a program for the serology test developers. And I forget the latest number on serology tests, but we authorized almost 90, if not over 90 serology tests, many of them lateral flow devices very similar to antigen tests through that program. And it's an interesting idea, and very willing to take that back. That program at the NCI was funded. And it took a lot of money to do that program. I don't know if the budget numbers are public. But I know the amount and it was not insignificant. And obviously, I would be very supportive of something like that, because an independent assessment by the US government is quite valuable. And as we found out with the serology test, and I think I've mentioned this multiple times before on this call, those tests that were submitted to NCI and were cleared by the FDA to be tested at NCI, we did an initial review of all submissions only recommended to NCI those tests that after our initial review seemed important to test. So we did eliminate from the list before NCI tested, and still something like 60% to 70% of the tests that had passed that first FDA review failed at NCI. And so this kind of program can be very helpful for challenging questions. And I think it's a really good idea and definitely will take that back.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: serology evaluation program, antigen test validation, government-funded testing programs
REVIEW FLAG: False

QA Block 11-9
CLARIFIED QUESTION: What are the limitations or bottlenecks preventing non-US companies from accessing funds aimed at increasing rapid test availability in the US?
CLARIFIED ANSWER: Funding appears to prioritize US-based companies, creating bottlenecks for non-US companies, despite having market-ready and validated products.
VERBATIM QUESTION: What are the limitations or bottlenecks preventing non-US companies from accessing funds aimed at increasing rapid test availability in the US?
VERBATIM ANSWER: But what I do see, though, is that a lot of those funds are going only to US-based companies. And while the approach looks great, but the truth is that there is a lot of bottlenecks, that these companies are not easily able to bring products to market, where test developers like us and many others, I'm sure, we have the products ready. I mean, these products are being sold elsewhere and they have demonstrated to be good.
SPEAKER QUESTION: Franco Calderon
SPEAKER ANSWER: Franco Calderon
TOPICS: funding limitations, non-US company challenges, rapid test availability
REVIEW FLAG: False

QA Block 11-10
CLARIFIED QUESTION: Would the FDA support or recommend alternative government strategies for purchasing and distributing diagnostic tests outside of commercial channels?
CLARIFIED ANSWER: The FDA's stance is that decisions on alternative purchasing and distribution strategies should be made by the US government, not the FDA, but the suggestion will be relayed.
VERBATIM QUESTION: Would the FDA support or recommend alternative government strategies for purchasing and distributing diagnostic tests outside of commercial channels?
VERBATIM ANSWER: And the other thing is I think the US government should consider novel approaches to purchasing and distributing tests outside of commercial channels. But that's not up for me, or nor do I think it's up to the FDA to decide. So I will take those ideas back.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: alternative test distribution, government strategies
REVIEW FLAG: False


#### 12. Guidance on Modifying EUA-Authorized Diagnostic Tests

QA Block 12-1
CLARIFIED QUESTION: Once satisfied that performance is equivalent to the current authorized test, can we implement changes to an EUA test in high complexity CLIA labs while the EUA is under FDA review?
CLARIFIED ANSWER: Modifications to a commercial diagnostic COVID test can be implemented in high complexity CLIA labs once the amendment requesting authorization for the modification has been submitted.
VERBATIM QUESTION: Once satisfied that performance is equivalent to the current authorized test, can we implement changes to an EUA test in high complexity CLIA labs while the EUA is under FDA review?
VERBATIM ANSWER: That's right. For modifications to a commercial diagnostic COVID test, once you've submitted your amendment to request authorization for the modification, you can implement that in high complexity labs.
SPEAKER QUESTION: Richard Montagna
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA test modification, High complexity CLIA labs, Implementation timing
REVIEW FLAG: False

QA Block 12-2
CLARIFIED QUESTION: When submitting the EUA along with a cover letter, should it indicate that we are going to immediately implement software changes?
CLARIFIED ANSWER: FDA stated that for modifications to a commercial COVID diagnostic test, once the amendment for authorization is submitted, the implementation can proceed in high complexity labs.
VERBATIM QUESTION: When submitting the EUA along with a cover letter, should it indicate that we are going to immediately implement software changes?
VERBATIM ANSWER: For modifications to a commercial diagnostic COVID test, once you've submitted your amendment to request authorization for the modification, you can implement that in high complexity labs.
SPEAKER QUESTION: Richard Montagna
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA submission, software changes, high complexity labs
REVIEW FLAG: False

QA Block 12-3
CLARIFIED QUESTION: Could you clarify the provisions or timeline for implementing modifications to a commercial diagnostic COVID test in high complexity labs?
CLARIFIED ANSWER: FDA stated that modifications to a commercial COVID diagnostic test can be implemented in high complexity labs after submitting an amendment for authorization.
VERBATIM QUESTION: Could you clarify the provisions or timeline for implementing modifications to a commercial diagnostic COVID test in high complexity labs?
VERBATIM ANSWER: For modifications to a commercial diagnostic COVID test, once you've submitted your amendment to request authorization for the modification, you can implement that in high complexity labs.
SPEAKER QUESTION: Richard Montagna
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA modifications, high complexity labs, COVID diagnostic tests
REVIEW FLAG: False

QA Block 12-4
CLARIFIED QUESTION: What is the exact time frame required for validating modifications to an EUA-authorized test before implementation in high complexity labs?
CLARIFIED ANSWER: After submitting an amendment for authorization of a modification to a COVID diagnostic test, it can be implemented in high complexity labs without waiting for FDA review.
VERBATIM QUESTION: IMPLICIT
VERBATIM ANSWER: Once you've submitted your amendment to request authorization for the modification, you can implement that in high complexity labs.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA modification timing, High complexity labs, COVID-19 test authorization
REVIEW FLAG: False

QA Block 12-5
CLARIFIED QUESTION: Is the timeline for validation of modifications similar to the validation of a new diagnostic device?
CLARIFIED ANSWER: The timeline for validating modifications is similar to the timeline for validating an entirely new diagnostic device, based on FDA guidance.
VERBATIM QUESTION: Is the timeline for validation of modifications similar to the validation of a new diagnostic device?
VERBATIM ANSWER: Yes, do read the policy guidance on this and adhere to the provisions, which I think there's a certain amount of time after you've validated the modification. I think it's a similar timeline as if you validate an entirely new device, and then the amount of time before you send it in.
SPEAKER QUESTION: Richard Montagna
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Validation timelines, EUA modifications
REVIEW FLAG: False

QA Block 12-6
CLARIFIED QUESTION: Should policy guidance for validating modifications also address the steps required for submitting amendments for authorization?
CLARIFIED ANSWER: FDA advises following the policy guidance on validating modifications and notes that after submitting an amendment for authorization, modifications can be implemented in high complexity labs without awaiting review.
VERBATIM QUESTION: Should policy guidance for validating modifications also address the steps required for submitting amendments for authorization?
VERBATIM ANSWER: Yes, do read the policy guidance on this and adhere to the provisions, which I think there's a certain amount of time after you've validated the modification. I think it's a similar timeline as if you validate an entirely new device, and then the amount of time before you send it in. I think with commercial devices-- and Toby, if you're still on-- that submission has to be made, but you don't have to wait on the review of the change or the device prior to launching that. For modifications to a commercial diagnostic COVID test, once you've submitted your amendment to request authorization for the modification, you can implement that in high complexity labs.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Policy guidance, Submitting amendments, COVID-19 test modifications
REVIEW FLAG: False

QA Block 12-7
CLARIFIED QUESTION: Are there any specific provisions for overseeing the implementation of software-related modifications in high complexity labs?
CLARIFIED ANSWER: Software modifications for commercial diagnostic COVID tests can be implemented in high complexity labs after submitting an amendment requesting authorization for the modification.
VERBATIM QUESTION: Are there any specific provisions for overseeing the implementation of software-related modifications in high complexity labs?
VERBATIM ANSWER: For modifications to a commercial diagnostic COVID test, once you've submitted your amendment to request authorization for the modification, you can implement that in high complexity labs.
SPEAKER QUESTION: Richard Montagna
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: software modifications, high complexity labs, EUA process
REVIEW FLAG: False


#### 13. Guidance for Antigen Test Validation and Submission Challenges

QA Block 13-1
CLARIFIED QUESTION: What do you recommend as a way or path forward for submission in the absence of feedback from FDA for validating multiplex devices, especially with a lack of prospective samples for influenza?
CLARIFIED ANSWER: FDA recommends resubmitting the pre-EUA to the Templates email and asking for specifics via Toby. Due to the lack of flu samples, developers should validate SARS-only targets initially and disable results for insufficiently validated analytes, reactivating them once validation data is available.
VERBATIM QUESTION: What do you recommend as a way or path forward for submission in the absence of feedback from FDA for validating multiplex devices, especially with a lack of prospective samples for influenza?
VERBATIM ANSWER: If that's been more than a couple of weeks since you submitted your pre-EUA, please send it back to the Templates email and ask please ask for Toby to get connected to find out if we can give you even more specifics about your submission. But this is a challenge. So particularly with antigen devices, bank samples can be challenging if they're not banked direct swabs. And people just don't typically bank direct swabs. And so we've seen so many issues with antigen tests. And we've removed VTM from a number of antigen test authorizations for this pandemic because of the issues we've seen with VTM. VTM can raise the baseline, artificially increase the sensitivity of device, and then raise the false positive rate. So that we're really not pleased with VTM. So this is a really, really challenging question, because we have so many already fully authorized flu point-of-care and central molecular tests for flu. And the flu is not the pandemic virus-- the pandemic virus that gives us authorities, some of the EUA processes for SARS-CoV-2, COVID. But we've tried to be as flexible as possible and stretch those authorities as far as possible and to help out here. The good thing is there's not any flu now and there may not be any flu this season. So that the other thing that we've consistently messaged is, if you're not able to get validation done for the non-SARS targets on your device due to the fact that you can't get appropriate bank samples, and you can't get those positives prospectively that are fresh, look at how you can somehow turn off the results for those other analytes that you don't have enough positives to get an authorization for. And sometimes that's more challenging, say, for a non-instrumented- or non-smartphone-read rapid antigen test because it's a visual read. And your top cassette may say flu A for the SARS on it, but we'll be imaginative and creative in what you can do in that situation. For example, if the window is too big for SARS because the home user might or the point-of-care user might see the flu bands and get confused, then they can make that window smaller. You may be able to remove identifiers from those extra bands if people will not be confused by those extra bands. If it's a smartphone reader or instrumented device, you can simply turn off the reporting from those bands until those are authorized. So you can get an initial authorization for SARS only. And then once you accumulate enough data and can submit the additional data for the additional targets, those things can be turned on, physically or electronically, whatever is the possible way. So that's what we've done for prior devices prior to the pandemic. And BioFire is a great example where they have this huge panel of respiratory viruses and sometimes other panels. And they may or may not get enough data for the less common targets. But they go ahead and get authorization for what they can get at the time, and then they update their submission and expand their authorization. So trying to be as flexible as possible. At the end of the day, we need to know if these flu or other non- SARS targets actually work so that patients are getting accurate information.
SPEAKER QUESTION: Kelly Leanhart
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Multiplex device submissions, Validation with limited influenza samples, FDA submission guidance
REVIEW FLAG: False

QA Block 13-2
CLARIFIED QUESTION: When I resubmit, should I request that the information gets forwarded to Toby?
CLARIFIED ANSWER: Yes, you should request for the information to be forwarded to Toby when you resubmit.
VERBATIM QUESTION: When I resubmit, should I request that the information gets forwarded to Toby?
VERBATIM ANSWER: Correct.
SPEAKER QUESTION: Kelly Leanhart
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Submission process, Forwarding information
REVIEW FLAG: False

QA Block 13-3
CLARIFIED QUESTION: When can I expect the more recent transcripts of the FDA town halls to be posted?
CLARIFIED ANSWER: The FDA aims to post the more recent town hall transcripts by Monday to catch up and is working on addressing the delay.
VERBATIM QUESTION: When can I expect the more recent transcripts of the FDA town halls to be posted?
VERBATIM ANSWER: I actually have a couple of the transcripts in hand right now. I'm hoping to get them posted by Monday to at least catch us up through to the last town hall. And I'm working towards getting that one together as well. So I apologize that we are a little bit behind on the transcripts. We are working to get that addressed and get them posted as soon as possible.
SPEAKER QUESTION: Kelly Leanhart
SPEAKER ANSWER: Joseph Tartal (FDA)
TOPICS: FDA town hall transcripts, Posting timeline
REVIEW FLAG: False

QA Block 13-4
CLARIFIED QUESTION: Should I submit everything as-is and explain to FDA?
CLARIFIED ANSWER: Yes, submit everything as is and include an explanation.
VERBATIM QUESTION: Should I submit everything as-is and explain to FDA?
VERBATIM ANSWER: Yeah, yeah.
SPEAKER QUESTION: Kelly Leanhart
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: submission process, pre-EUA guidance
REVIEW FLAG: False

QA Block 13-5
CLARIFIED QUESTION: Should I provide my pre-EUA number when resubmitting my question?
CLARIFIED ANSWER: You should include your pre-EUA number when resubmitting your question to ensure it is properly processed.
VERBATIM QUESTION: Should I provide my pre-EUA number when resubmitting my question?
VERBATIM ANSWER: Or just provide your pre-EUA number.
SPEAKER QUESTION: Kelly Leanhart
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: pre-EUA submission, resubmission process
REVIEW FLAG: False

QA Block 13-6
CLARIFIED QUESTION: Why is VTM (viral transport media) discouraged for use with antigen tests?
CLARIFIED ANSWER: FDA discourages the use of VTM for antigen tests because it can raise the baseline, artificially increase sensitivity, and lead to a higher false positive rate.
VERBATIM QUESTION: Why is VTM (viral transport media) discouraged for use with antigen tests?
VERBATIM ANSWER: VTM can raise the baseline, artificially increase the sensitivity of device, and then raise the false positive rate. So that we're really not pleased with VTM.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: VTM issues, Antigen test sensitivity, False positives
REVIEW FLAG: False

QA Block 13-7
CLARIFIED QUESTION: What are the acceptable alternatives to banked direct swabs for antigen test validation?
CLARIFIED ANSWER: The FDA discourages the use of VTM due to its issues in antigen test validation. If banked direct swabs or fresh positives are unavailable, developers can disable reporting for non-SARS targets, adjust windows for clarity, or remove extra band identifiers. SARS-only authorization can be pursued, with expanded authorization possible later upon submitting additional data.
VERBATIM QUESTION: What are the acceptable alternatives to banked direct swabs for antigen test validation?
VERBATIM ANSWER: So particularly with antigen devices, bank samples can be challenging if they're not banked direct swabs. And people just don't typically bank direct swabs. And so we've seen so many issues with antigen tests. And we've removed VTM from a number of antigen test authorizations for this pandemic because of the issues we've seen with VTM. VTM can raise the baseline, artificially increase the sensitivity of device, and then raise the false positive rate. So that we're really not pleased with VTM. So if you're not able to get validation done for the non-SARS targets on your device due to the fact that you can't get appropriate bank samples, and you can't get those positives prospectively that are fresh, look at how you can somehow turn off the results for those other analytes that you don't have enough positives to get an authorization for. For example, if the window is too big for SARS because the home user might or the point-of-care user might see the flu bands and get confused, then they can make that window smaller. You may be able to remove identifiers from those extra bands if people will not be confused by those extra bands. If it's a smartphone reader or instrumented device, you can simply turn off the reporting from those bands until those are authorized. So you can get an initial authorization for SARS only. And then once you accumulate enough data and can submit the additional data for the additional targets, those things can be turned on, physically or electronically, whatever is the possible way.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Antigen test validation, Alternatives to VTM, SARS-only authorization
REVIEW FLAG: False

QA Block 13-8
CLARIFIED QUESTION: How can antigen test manufacturers address challenges with visual read devices that include multiple analytes, such as flu and SARS?
CLARIFIED ANSWER: The FDA suggests device manufacturers address validation challenges by focusing on SARS-only authorizations initially. For visual read devices, reduce confusion by modifying the display, such as resizing or removing irrelevant bands or identifiers, until sufficient validation data for flu or other targets can be obtained and additional authorizations can follow.
VERBATIM QUESTION: How can antigen test manufacturers address challenges with visual read devices that include multiple analytes, such as flu and SARS?
VERBATIM ANSWER: So particularly with antigen devices, bank samples can be challenging if they're not banked direct swabs. And people just don't typically bank direct swabs. And so we've seen so many issues with antigen tests. And we've removed VTM from a number of antigen test authorizations for this pandemic because of the issues we've seen with VTM. VTM can raise the baseline, artificially increase the sensitivity of device, and then raise the false positive rate. So that we're really not pleased with VTM. So this is a really, really challenging question, because we have so many already fully authorized flu point-of-care and central molecular tests for flu. And the flu is not the pandemic virus-- the pandemic virus that gives us authorities, some of the EUA processes for SARS-CoV-2, COVID. But we've tried to be as flexible as possible and stretch those authorities as far as possible and to help out here. The good thing is there's not any flu now and there may not be any flu this season. So that the other thing that we've consistently messaged is, if you're not able to get validation done for the non-SARS targets on your device due to the fact that you can't get appropriate bank samples, and you can't get those positives prospectively that are fresh, look at how you can somehow turn off the results for those other analytes that you don't have enough positives to get an authorization for. And sometimes that's more challenging, say, for a non-instrumented- or non-smartphone-read rapid antigen test because it's a visual read. And your top cassette may say flu A for the SARS on it, but we'll be imaginative and creative in what you can do in that situation. For example, if the window is too big for SARS because the home user might or the point-of-care user might see the flu bands and get confused, then they can make that window smaller. You may be able to remove identifiers from those extra bands if people will not be confused by those extra bands. If it's a smartphone reader or instrumented device, you can simply turn off the reporting from those bands until those are authorized. So you can get an initial authorization for SARS only. And then once you accumulate enough data and can submit the additional data for the additional targets, those things can be turned on, physically or electronically, whatever is the possible way. So that's what we've done for prior devices prior to the pandemic.
SPEAKER QUESTION: Kelly Leanhart
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Antigen test validation, Visual read device modifications, Flu and SARS multiplex testing
REVIEW FLAG: False

QA Block 13-9
CLARIFIED QUESTION: What should developers do if there are no flu cases to validate influenza targets for multiplex devices?
CLARIFIED ANSWER: If flu cases aren't available for validation, developers should consider turning off the influenza reporting functionality in their devices temporarily and seek authorization for SARS only. Validation and reporting for flu can be added later when data becomes available.
VERBATIM QUESTION: What should developers do if there are no flu cases to validate influenza targets for multiplex devices?
VERBATIM ANSWER: The good thing is there's not any flu now and there may not be any flu this season. So that the other thing that we've consistently messaged is, if you're not able to get validation done for the non-SARS targets on your device due to the fact that you can't get appropriate bank samples, and you can't get those positives prospectively that are fresh, look at how you can somehow turn off the results for those other analytes that you don't have enough positives to get an authorization for. And sometimes that's more challenging, say, for a non-instrumented- or non-smartphone-read rapid antigen test because it's a visual read. And your top cassette may say flu A for the SARS on it, but we'll be imaginative and creative in what you can do in that situation. For example, if the window is too big for SARS because the home user might or the point-of-care user might see the flu bands and get confused, then they can make that window smaller. You may be able to remove identifiers from those extra bands if people will not be confused by those extra bands. If it's a smartphone reader or instrumented device, you can simply turn off the reporting from those bands until those are authorized. So you can get an initial authorization for SARS only. And then once you accumulate enough data and can submit the additional data for the additional targets, those things can be turned on, physically or electronically, whatever is the possible way.
SPEAKER QUESTION: Kelly Leanhart
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: flu case validation, multiplex device authorization, FDA guidance
REVIEW FLAG: False

QA Block 13-10
CLARIFIED QUESTION: Can additional targets on a multiplex device be turned off to allow for partial authorization for only SARS-CoV-2?
CLARIFIED ANSWER: For smartphone or instrumented devices, additional targets on a multiplex device can have their reporting turned off to achieve initial authorization for SARS-CoV-2. Once sufficient data is collected for the other targets, they can be reactivated.
VERBATIM QUESTION: Can additional targets on a multiplex device be turned off to allow for partial authorization for only SARS-CoV-2?
VERBATIM ANSWER: If it's a smartphone reader or instrumented device, you can simply turn off the reporting from those bands until those are authorized. So you can get an initial authorization for SARS only. And then once you accumulate enough data and can submit the additional data for the additional targets, those things can be turned on, physically or electronically, whatever is the possible way.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Multiplex device target reporting, SARS-CoV-2 authorization, Device data requirements
REVIEW FLAG: False

QA Block 13-11
CLARIFIED QUESTION: What steps are needed to re-enable other analytes on a multiplex test once sufficient data is available for validation and authorization?
CLARIFIED ANSWER: Developers can initially disable analytes not yet validated and approved, then later submit additional data for those analytes to enable them once authorized. Methods may be physical or electronic, depending on the device.
VERBATIM QUESTION: What steps are needed to re-enable other analytes on a multiplex test once sufficient data is available for validation and authorization?
VERBATIM ANSWER: If it's a smartphone reader or instrumented device, you can simply turn off the reporting from those bands until those are authorized. So you can get an initial authorization for SARS only. And then once you accumulate enough data and can submit the additional data for the additional targets, those things can be turned on, physically or electronically, whatever is the possible way. So that's what we've done for prior devices prior to the pandemic. And BioFire is a great example where they have this huge panel of respiratory viruses and sometimes other panels. And they may or may not get enough data for the less common targets. But they go ahead and get authorization for what they can get at the time, and then they update their submission and expand their authorization.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Multiplex test analytes, Validation and authorization, Device reporting adjustments
REVIEW FLAG: False

QA Block 13-12
CLARIFIED QUESTION: Are there specific considerations for modifying test designs to prevent user confusion when testing for multiple analytes?
CLARIFIED ANSWER: If validation for non-SARS targets isn't possible, FDA suggests turning off results for unanalyzed targets. For visual-read tests, adjustments like reducing window size or removing identifiers can prevent confusion. For electronic readers, disable reporting for unapplied targets until authorized.
VERBATIM QUESTION: Are there specific considerations for modifying test designs to prevent user confusion when testing for multiple analytes?
VERBATIM ANSWER: The other thing that we've consistently messaged is, if you're not able to get validation done for the non-SARS targets on your device due to the fact that you can't get appropriate bank samples, and you can't get those positives prospectively that are fresh, look at how you can somehow turn off the results for those other analytes that you don't have enough positives to get an authorization for. And sometimes that's more challenging, say, for a non-instrumented- or non-smartphone-read rapid antigen test because it's a visual read. And your top cassette may say flu A for the SARS on it, but we'll be imaginative and creative in what you can do in that situation. For example, if the window is too big for SARS because the home user might or the point-of-care user might see the flu bands and get confused, then they can make that window smaller. You may be able to remove identifiers from those extra bands if people will not be confused by those extra bands. If it's a smartphone reader or instrumented device, you can simply turn off the reporting from those bands until those are authorized. So you can get an initial authorization for SARS only. And then once you accumulate enough data and can submit the additional data for the additional targets, those things can be turned on, physically or electronically, whatever is the possible way.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Modifying test designs, Preventing user confusion, Multiple analyte testing
REVIEW FLAG: False


#### 14. COVID-19 Diagnostic Pathways and Manufacturer Notifications Update

QA Block 14-1
CLARIFIED QUESTION: Are the notification pathways for antibody tests still viable pathways for manufacturers to use in order to market to high complexity settings while waiting for their EUA?
CLARIFIED ANSWER: The FDA confirms that notification pathways remain open as per current guidance. Manufacturers should contact the FDA if devices are not appearing on the notification page, as commercial manufacturers are typically required to notify.
VERBATIM QUESTION: Are the notification pathways for antibody tests still viable pathways for manufacturers to use in order to market to high complexity settings while waiting for their EUA?
VERBATIM ANSWER: The notification pathways as spelled out in the current guidance are still open. I was not aware perhaps that some devices weren't showing up timely in the notification page. If that's the case, then that those developers should just reach out to the FDA and ask. Sometimes we don't require that notification to be posted, but I think for all commercial manufacturers we do.
SPEAKER QUESTION: Samantha Eakes
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: notification pathways, antibody tests, manufacturer EUA
REVIEW FLAG: False

QA Block 14-2
CLARIFIED QUESTION: What should manufacturers do if their device notifications do not appear timely on the FDA notification page?
CLARIFIED ANSWER: Manufacturers should contact the FDA if their device notifications do not appear timely on the notification page, as FDA typically requires postings for all commercial manufacturers.
VERBATIM QUESTION: What should manufacturers do if their device notifications do not appear timely on the FDA notification page?
VERBATIM ANSWER: If that's the case, then that those developers should just reach out to the FDA and ask. Sometimes we don't require that notification to be posted, but I think for all commercial manufacturers we do.
SPEAKER QUESTION: Samantha Eakes
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: FDA notification pathways, manufacturer device postings, response protocols
REVIEW FLAG: False

QA Block 14-3
CLARIFIED QUESTION: Are there any cases where commercial manufacturers are exempt from the requirement to post notification for their devices?
CLARIFIED ANSWER: FDA typically requires all commercial manufacturers to post notification for their devices.
VERBATIM QUESTION: Are there any cases where commercial manufacturers are exempt from the requirement to post notification for their devices?
VERBATIM ANSWER: Sometimes we don't require that notification to be posted, but I think for all commercial manufacturers we do.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: notification requirements, commercial manufacturers
REVIEW FLAG: False


#### 15. Acceptability of Lab-Validated Specimens in Clinical Trials

QA Block 15-1
CLARIFIED QUESTION: In a clinical trial for a multi-analyte antigen detection test, if a reference RT-PCR assay does not have claims for a specific specimen type, but the reference laboratory we're using has validated that specimen type, is it acceptable to use the results from that lab-validated specimen as a reference?
CLARIFIED ANSWER: FDA recommends using fully EUA-authorized methods or fully cleared molecular tests without LDT modifications as comparators, as modifications to tests require FDA review and can make the process inefficient.
VERBATIM QUESTION: In a clinical trial for a multi-analyte antigen detection test, if a reference RT-PCR assay does not have claims for a specific specimen type, but the reference laboratory we're using has validated that specimen type, is it acceptable to use the results from that lab-validated specimen as a reference?
VERBATIM ANSWER: If it's modifications to an EUA test and the FDA hasn't reviewed and authorized those modifications, that's a challenge. If it's a fully cleared device and modifications have been made that haven't been FDA authorized, that is a challenge. We're not going to say no. But basically the modifications to the test would have to be reviewed and found to be authorizable, at the very least, in order for us to accept that data. So then you're asking our review team to not-- and actually, if it's an antigen test, then the antigen team would be reviewing the antigen test, and the molecular team would be reviewing the modifications to a molecular test. So that's just terribly inefficient. So that's why we do recommend that you use fully EUA- authorized methods that are acceptable as a comparator. Those are high sensitivity molecular tests. Or you can use a fully cleared or authorized molecular test without LDT modification. That's our recommendation. Once they know how to do it, but it will really muck up the system more than needed.
SPEAKER QUESTION: Mary Ann
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Multi-analyte antigen tests, EUA-authorized comparators, Modifications to diagnostic tests
REVIEW FLAG: False

QA Block 15-2
CLARIFIED QUESTION: What are the FDA's recommendations for using EUA-authorized methods as comparators in test validations?
CLARIFIED ANSWER: FDA recommends using fully EUA-authorized high-sensitivity molecular methods or fully cleared/authorized molecular tests without LDT modifications as comparators in test validations.
VERBATIM QUESTION: What are the FDA's recommendations for using EUA-authorized methods as comparators in test validations?
VERBATIM ANSWER: If it's modifications to an EUA test and the FDA hasn't reviewed and authorized those modifications, that's a challenge. If it's a fully cleared device and modifications have been made that haven't been FDA authorized, that is a challenge. We're not going to say no. But basically the modifications to the test would have to be reviewed and found to be authorizable, at the very least, in order for us to accept that data. So then you're asking our review team to not-- and actually, if it's an antigen test, then the antigen team would be reviewing the antigen test, and the molecular team would be reviewing the modifications to a molecular test. So that's just terribly inefficient. So that's why we do recommend that you use fully EUA- authorized methods that are acceptable as a comparator. Those are high sensitivity molecular tests. Or you can use a fully cleared or authorized molecular test without LDT modification. That's our recommendation.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA-authorized comparator methods, Test validation, Molecular test recommendations
REVIEW FLAG: False

QA Block 15-3
CLARIFIED QUESTION: Can a molecular test with laboratory-developed test (LDT) modifications be used without additional FDA review?
CLARIFIED ANSWER: The FDA recommends using fully EUA-authorized methods or fully cleared molecular tests without LDT modifications since unauthorized modifications pose significant challenges and inefficiencies.
VERBATIM QUESTION: Can a molecular test with laboratory-developed test (LDT) modifications be used without additional FDA review?
VERBATIM ANSWER: If it's modifications to an EUA test and the FDA hasn't reviewed and authorized those modifications, that's a challenge. If it's a fully cleared device and modifications have been made that haven't been FDA authorized, that is a challenge. We're not going to say no. But basically the modifications to the test would have to be reviewed and found to be authorizable, at the very least, in order for us to accept that data. So then you're asking our review team to not-- and actually, if it's an antigen test, then the antigen team would be reviewing the antigen test, and the molecular team would be reviewing the modifications to a molecular test. So that's just terribly inefficient. So that's why we do recommend that you use fully EUA- authorized methods that are acceptable as a comparator. Those are high sensitivity molecular tests. Or you can use a fully cleared or authorized molecular test without LDT modification. That's our recommendation. Once they know how to do it, but it will really muck up the system more than needed.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: molecular test modifications, FDA authorization, laboratory-developed tests (LDTs)
REVIEW FLAG: False

QA Block 15-4
CLARIFIED QUESTION: What does the FDA mean by 'authorizable' when describing test modifications?
CLARIFIED ANSWER: The FDA considers test modifications 'authorizable' if they can be reviewed and deemed acceptable for authorization during their review process.
VERBATIM QUESTION: What does the FDA mean by 'authorizable' when describing test modifications?
VERBATIM ANSWER: But basically the modifications to the test would have to be reviewed and found to be authorizable, at the very least, in order for us to accept that data.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: test modifications, authorization criteria, EUA processes
REVIEW FLAG: False
